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Environmental signals, including cytokines, received by CD8+ T cells during the 
primary response to acute infection shape their commitment to effector and memory 
CD8+ T cell fates, as well as their ability to respond to future pathogen challenges.  The 
common gamma chain (γc) cytokine interleukin-2 (IL-2) provides a memory 
differentiation signal during the primary response that programs CD8+ T cells for 
successful recall responses later.  We find that although primary effector CTL 
development is modestly decreased in the absence of IL-2, the persistence of terminal 
effector phenotype and tissue residing memory CD8+ T cell populations after pathogen 
clearance is greatly diminished.  Furthermore, memory CD8+ T cells generated in the 
absence of IL-2 signals are unable to undergo secondary effector CTL differentiation.  
We conclude that IL-2 promotes entry into and survival within an effector CD8+ T cell 
differentiation program.  
The role of IL-2 in promoting primary and secondary effector CTL 
differentiation is not shared by the highly related cytokine, IL-15.  Although IL-15 
supports the survival of effector phenotype CD8+ T cells after pathogen clearance, its 
absence does not impair either primary or secondary effector CTL differentiation, nor 
does it impact the differentiation of long-term effector memory CD8+ T cells.  Thus, 
there is a unique role for IL-2, but not IL-15, in promoting the differentiation of effector 
CTL and programming memory CD8+ T cells capable of secondary effector 
differentiation.   
 
 iv 
How CD8+ T cells integrate IL-2 signals and the molecular nature of these 
signals in the development of functional memory populations is not understood. 
Because IL-2 induces potent activation of the STAT5 transcription factor, we tested the 
role of STAT5 in CD8+ effector and memory differentiation.  We find that STAT5 
activity is broadly important for the expansion and effector functions of all effector CTL 
subsets during the primary response.  Despite a broad role in expansion, the 
requirement for STAT5 was particularly important for survival of terminal effector 
phenotype and tissue residing memory CD8+ T cells after pathogen clearance.  
Surprisingly, although STAT5 was important in primary effector CTL responses, and 
unlike IL-2, STAT5 activity is not required for the development of memory CD8+ T cells 
capable of robust secondary expansion and secondary effector differentiation upon 
rechallenge.  These findings highlight differential requirements for survival signals 
between primary and secondary effector CTL, and subsets of memory CD8+ T cells.  
Furthermore, we demonstrate that IL-2 dependent programming of memory CD8+ T 
cells capable of protective recall responses is STAT5 independent.
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CD8+ T cell response to acute infection 
Naïve CD8+ T cells circulate through the host lymphoid system, continually 
sampling antigens being presented by antigen presenting cells in the secondary 
lymphoid organs.  Upon encounter with cognate antigen, CD8+ T cells undergo a period 
of massive expansion, lasting approximately 7-8 days in the case of acute infection[1].  
During this time, in which these CD8+ T cells are referred to as effector CD8+ T cells or 
cytolytic T cells (CTLs), they acquire essential effector functions required for pathogen 
clearance.   These effector functions include the ability to migrate to the site of infection, 
specific killing of infected target cells by cytolysis, involving granzymes and perforin or 
via Fas/FasL, and the secretion of pro-inflammatory cytokines, such as IFN-γ and TNF-
α[2].  After the pathogen is cleared, a period of contraction ensues, in which nearly all of 
the effector CD8+ T cell pool will die by apoptosis.  However, a small percentage 
(approximately 5-10%) of the CD8+ T cells will survive and go on to form a long-lived 
population of memory CD8+ T cells[1].   
Hallmarks of memory CD8+ T cells 
A defining feature of adaptive immunity is immunological memory, which results 
in protection of the host from reinfection with the same or related pathogens.  Memory 
CD8+ T cells that form after primary exposure to antigen have several properties that 
distinguish them from naïve CD8+ T cells that have no previous antigen exposure.  First, 
memory CD8+ T cells are present in the host at higher frequencies than naïve CD8+ T 
cells. These memory populations are able to persist for long periods, often the lifetime of 
the host, through self-renewal via slow homeostatic turnover.  Upon secondary exposure 
to cognate antigen, memory CD8+ T cells rapidly expand and reacquire their effector 
functions (recall).  The combined result of these memory CD8+ T cell properties is the 
clearance of pathogen upon subsequent exposure, often before the host experiences 
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symptoms of infection.  The factors regulating longevity of memory CD8+ T cells and 
optimal CD8+ T cell recall responses are of great interest, yet are not fully understood. 
Models of memory CD8+ T cell differentiation  
and CD8+ T cell fate decisions 
How a small fraction of memory CD8+ T cells is selected to survive after pathogen 
clearance while the majority of the effector CD8+ T cell pool dies is not understood.  After 
initial antigen encounter, CTL differentiation and proliferation occur independent of 
antigen, and the development of a memory CD8+ T cell population [3].  It has been 
shown that a single CD8+ T cell is able to give rise to both effector and memory CD8+ T 
cell pools [4, 5], demonstrating that memory potential is not pre-programmed.  Studies 
in which antigen presentation is curtailed show that commitment to memory CD8+ T cell 
lineage occurs early during an immune response, likely within the first 1-3 days of 
antigen exposure [6, 7].   Moreover, the composition of the effector and memory CD8+ T 
cell pools is heterogeneous in regards to cell surface phenotype, expression of effector 
molecules, long-term survival and turnover, and proliferative potential during recall [8, 
9].   
 Several models have been proposed to describe the differentiation of protective 
memory CD8+ T cells from the effector CD8+ T cell pool [10].  The existence of multiple 
subsets of effector and memory CD8+ T cells with different longevity suggests that 
memory CD8+ T cell differentiation is an ongoing process during the effector phase into 
contraction, and into the early memory phase [11, 12].  Of the proposed models, the most 
likely scenario is a model in which CD8+ T cells commit to a terminal fate (death after 
pathogen clearance) or memory fate (potential to seed the memory CD8+ T cell pool) 
early during the immune response.  Additional environmental signals likely promote a 
more or less differentiated effector state within these populations, and those CD8+ T cells 
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that have the potential to seed the memory pool will still undergo progressive 
differentiation over time after pathogen clearance during which time they will ultimately 
acquire the hallmarks of protective, fully differentiated memory CD8+ T cell.  
Consistent with such a model, it has been shown that at the peak of the effector 
CD8+ T cell response to the acute virus LCMV-Armstrong, two distinct populations 
within the effector CD8+ T cell pool can be distinguished that differ in their longevity 
within the memory CD8+ T cell pool [13].  These two populations can be distinguished 
based on differential expression of the cell surface molecules KLRG1 and IL7Rα (CD127) 
[13-15].  CD8+ T cells falling in one population, expressing high levels of KLRG1 and low 
levels of IL7Rα, herein called terminal effector phenotype CD8+ T cells, gradually decline 
after pathogen clearance [13].  CD8+ T cells falling in the second population, termed 
memory precursor or memory phenotype effector CD8+ T cells, express low levels of 
KLRG1 and high levels of IL7Rα.  This population is enriched for the potential to seed 
the memory CD8+ T cell pool, has more robust proliferative capacity than terminal 
effectors and over time, the circulating memory CD8+ T cell pool will evolve to be nearly 
entirely composted of this phenotype.  The existence of such populations shows that 
signals received by effector CD8+ T cells during the primary response after antigen 
stimulation regulate CD8+ T cell effector and memory fate decisions.   
 While the differential expression of KLRG1 and IL7Rα are useful markers for 
identifying CD8+ T cells that have increased long lived memory potential, they do not 
themselves drive CD8+ T cell differentiation, but instead are indicative of fate decisions 
made earlier.  Forcing expression of IL7Rα by effector CD8+ T cells does not increase 
memory potential [16, 17].  KLRG1 was found to be upregulated on terminally 
differentiated CD8+ T cells following LCMV infection of mice [18].  These KLRG1hi CD8+ 
T cells were potent effector CTL, but were resistant to secondary proliferation upon re-
exposure to antigen.  It was subsequently shown to be upregulated within CD8+ T cells 
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that had low IL7Rα expression [13].  Knockdown of KLRG1 expression in CD8+ T cells 
had no effect on their effector differentiation[13]. In addition, not all of the CD8+ T cells 
with an IL7Rahi phenotype will survive to seed the memory CD8+ T cell pool, and the 
CD8+ T cells within this subset also change in their secondary proliferative potential as 
they mature into the memory phase [14, 15].  Moreover, it is unclear to what extent these 
different subpopulations are able to protect from secondary challenge. Although 
terminal effector phenotype CD8+ T cells have less proliferative potential, they readily 
exert their effector functions [18] and thus may provide a frontline of protection from 
reinfection.   
 In addition to the heterogeneity seen within the effector CD8+ T cell pool, 
different subsets of IL7Rαhi memory CD8+ T cells emerge as well [1, 8-10].  In general, 
memory CD8+ T cells can be divided into two subsets, central memory (TCM) and effector 
memory (TEM) which differ in their anatomical location, cell surface phenotype, 
expression of effector molecules, and proliferative potential.  Broadly, TCM are found 
within the secondary lymphoid organs, are CD62LhiCCR7hi, do not immediately express 
effector molecules, and have high proliferative potential.  TEM, on the other hand, are 
found in peripheral nonlymphoid tissues, are CD62LloCCR7lo, display some effector 
molecule expression, and have low proliferative potential.  However, memory CD8+ T 
cells with mixed phenotypes also exist, and expression of these two markers may not be 
the best predictor of proliferative and/or protective potential upon recall [19].  Moreover, 
the lineage relationship of effector and memory CD8+ T cell subsets as well as the actual 
protective capacity of TCM versus TEM, remain controversial and unclear.  
Much progress has been made in identifying subsets present within effector and 
memory CD8+ T cell pools.  However, the signals that drive formation of these subsets 
and the signals that regulate CD8+ T cell fate decisions are still not well understood.  In 
addition, the degree of plasticity within commitment to a particular effector or memory 
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CD8+ T cell subset, the permanence or irreversibility of lineage commitment, and the 
signals that may be involved in commitment, are not well understood.  It is possible that 
after initial commitment, inflammation or cytokines in the environment could serve to 
further drive CD8+ T cells toward a more differentiated state [13].  It is also worth noting 
that although common model systems are used to study in vivo T cell responses and 
memory formation, it is still unclear if for different infectious conditions, if common 
and/or distinct pathways are used in CD8+ T cell fate decisions.  
 Many signals converge on CD8+ T cells during an immune response.  These 
include signals through the T cell receptor (TCR) delivered by antigen stimulation, 
costimulatory signals from antigen-presenting cells, and signals from cytokines and Type 
I interferons via receptors expressed on CD8+ T cells.  While TCR signal and 
costimulation are essential for initiation of CD8+ T cell responses, as discussed above, a 
relatively brief TCR stimulus is adequate to result in effector and memory CD8+ T cell 
generation [6, 7].  In addition, the CD8+ T cell TCR repertoire is similarly represented 
during effector and memory phases [20], suggesting that differences in TCR affinity do 
not regulate CD8+ T cell memory development.  Thus, signals derived from the 
environment during the primary response to infection, including inflammatory signals 
and those transmitted via cytokines and cytokine receptors, play a significant role in 
regulating CD8+ T cell fate decisions.  
Transcription Factors in CD8+ T cell fate decisions 
Several transcription factors have been shown to have crucial roles in CD8+ T cell 
effector differentiation and effector versus memory fate decisions.  These transcription 
factors are associated with either terminally differentiated effector or less differentiated 
long-lived memory CD8+ T cell states.  In the case of T-bet [13, 21-24] and Blimp-1 [25-
28], increased expression of these transcription factors promotes a more differentiated 
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terminal effector state in CD8+ T cells.  On the other hand, EOMES [22, 24, 29, 30] and 
Bcl-6 [25, 31, 32] are associated with establishment of memory CD8+ T cell populations 
and opposition of terminal effector differentiation.   
It has been shown in the case of T-bet that the pro-inflammatory cytokine IL-12 
can increase expression levels of T-bet and promote a more differentiated effector state 
in CD8+ T cells [13].  However, a direct connection between environmental signals, such 
as cytokines, received by CD8+ T cells during an immune response and the resulting 
transcriptional outcome driving differentiation towards short-lived effector versus 
memory precursor fate is not clear.  Although it is well established that several of these 
transcription factors are known to bind and regulate the promoters of genes regulating 
CTL function, such as Perforin, GzB, and IFNγ, how the transcriptional targets of these 
factors plays into resulting fate decisions in unknown.  It is not clear if these 
transcription factors promote effector vs memory differentiation by regulating genes that 
actually drive differentiation, or if they promote memory CD8+ T cell survival and 
secondary effector differentiation by allowing or restricting access to essential 
transcriptional programs.  
IL-2 signaling in programming of CD8+ T cell memory 
Common gamma chain (γc) cytokine family members are defined by their 
common use of the type I cytokine receptor subunit, γc (CD132), expressed on several 
leukocytes, including T cells.  This family includes several cytokines, which have been 
shown to play a role in naïve CD8+ T cell homeostasis and during CD8+ T cell effector 
and memory phases of the immune response [33].  Regulation of the specific subunits for 
each cytokine varies, resulting in different cytokine-specific stimulation of CD8+ T cells 
through the course of an immune response. 
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 The cytokine IL-2, a member of the γc cytokine family, is of interest in CD8+ T cell 
fate decisions and the main topic of this thesis.  IL-2 was originally named T cell growth 
factor because it resulted in proliferation of activated CD8+ T cells in vitro [34, 35].  
Surprisingly, initial studies regarding the in vivo role for IL-2 in promoting T cell 
proliferation and effector differentiation suggested that IL-2 was not required for 
successful primary T cell responses to infection [36-38].  However, these in vivo studies 
of IL-2 in CD8+ T cell responses to infection were complicated and difficult to interpret 
due to the requirement of IL-2 for maintenance of regulatory T cells [39], and the 
resulting development of lympho-proliferation and autoimmunity the absence of IL-2 or 
components of the IL-2 receptor [40-43].  The development of model systems where IL-
2 receptor components are absent, but a normal immune environment is present, has 
allowed revisiting of the role of IL-2 in effector and memory CD8+ T cell fate decisions 
[44, 45]. 
CD4+ T cell help has been shown to be required for memory CD8+ T cell 
programming [46-49].  In an attempt to understand how CD4+ T cells provide help to 
CD8+ T cells, the cytokine IL-2 was investigated as a potential driver of memory CD8+ T 
cell programming [45].  IL-2 is expressed at high levels mainly by activated CD4+ T cells, 
and to a lesser degree by CD8+ T cells and dendritic cells, during an active immune 
response.   In vivo examination of IL-2 production have shown that the production of IL-
2 peaks at 5-6 hours postantigen challenge, and is no longer detected after 16 hours [50, 
51].  In addition, expression of the trimeric IL-2R complex on activated CD8+ T cells 
(described in more detail below) is transient.  The result is a short window of time in 
which CD8+ T cells actively receive strong IL-2 signals early on during an immune 
response. 
Using an in vivo model with a normal immune environment, it was found that 
CD8+ T cells that do not receive IL-2 signals during primary immune response show only 
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modestly reduced levels of proliferation and effector CD8+ T cell expansion and readily 
formed long-lived memory CD8+ T cell populations upon pathogen clearance [44, 45].   
However, memory CD8+ T cells generated in the absence of IL-2 were phenotypically 
different than wildtype CD8+ T cells in that they skewed towards a central memory 
phenotype [45].  Most strikingly, memory CD8+ T cells generated in the absence of IL-2 
signals had defective recall responses upon secondary challenge [45].   This points to an 
essential role for the cytokine IL-2 in programming of memory CD8+ T cells capable of 
protective recall responses.  Moreover, this suggests that the recall capacity of memory 
CD8+ T cells (programming) is induced distinctly from survival of CD8+ T cells into the 
memory phase.  
IL-2 receptor signaling 
 The IL-2 receptor (IL-2R) is a trimeric complex consisting of the three subunits 
IL-2Rα(CD25), IL-2Rβ(CD122), and the common gamma chain, γc (CD132).  Expression 
of the three subunits is regulated differently, and the trimeric receptor is not present on 
resting CD8+ T cells.   Instead, the basal expression of β and γc subunits needs to be 
supplemented with expression of the high affinity receptor subunit, IL-2Rα[39], which 
occurs transiently at high levels upon CD8+ T cell activation[52].  After its expression is 
induced, the high affinity IL-2Rα subunit of the trimeric IL-2 receptor complex binds to 
IL-2 and subsequently associates with β and γc subunits, forming a stable quaternary 
complex [53, 54].  Although binding of IL-2 to the IL-2Rβ and γc subunits has been 
observed in vitro [55], it appears that this is unlikely to have an in vivo biological role, as 
concentrations of IL-2 required for functional signaling through the dimeric receptor are 
much higher than is found in vivo [56].  Moreover, IL-2-/- and CD25-/- mice develop 
similar autoimmune phenotypes [42, 43].  Thus, expression of IL-2Rα confers the ability 
of CD8+ T cells to receive IL-2 signals.  After the resolution of inflammation, CD8+ T cells 
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downregulate expression of CD25 and IL-2 is no longer robustly produced.  The result is 
strong yet transient signals received by CD8+ T cells during the effector phase of an 
immune response.  
 Signal transduction through the IL-2R occurs via the IL-2Rβ and γc receptor 
subunits [56, 57].  The Janus Kinase (JAK) family members JAK1 and JAK3 
constitutively associate with the cytoplasmic tails of IL-2Rβ and γc, respectively.  JAK1 
and JAK3 are activated immediately by autophosphorylation following receptor 
activation, and they subsequently trans-phosphorylate each other and also 
phosphorylate several tyrosine residues on the cytoplasmic tails of IL-2Rβ and γc.  This 
creates docking sites for signal transducer and activator of transcription family member 
5a and 5b, two mainly redundant isoforms of STAT5 in CD8+ T cells [58].  The associated 
STAT5 is then phosphorylated, mainly by JAK3, resulting in dimerization and 
translocation to the nucleus where it acts as a transcription factor and regulates gene 
expression important in T cell proliferation, survival, and effector differentiation.   
STAT3 is also recruited to phosphorylated tyrosines on the IL-2Rβ cytoplasmic tail, 
where it is phosphorylated and activated, but to a lesser extent than STAT5 [59, 60].  
 In addition to association with STAT5 and STAT3, the phosphorylated tail of IL-
2Rβ also associates with Shc, resulting in activation of mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways [56, 57].   Some reports 
have suggested that PI3K may be recruited to specific phosphorylated tyrosines on IL-
2Rβ cytoplasmic tail directly, and another report suggests activation of the PI3K pathway 
independent of cytoplasmic tyrosines on IL-2Rβ (reviewed in [56]).  Activation of the 
MAPK and PI3K pathways by IL-2 have been shown to be important in promoting T cell 
survival and proliferation [39, 56].   
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Topics addressed in this dissertation 
In Chapter 2, a thorough examination of effector CD8+ T cell responses in the 
absence of IL-2 is performed.  The result is an enhanced understanding of the role of IL-
2 in effector and memory CD8+ T cell fate decisions.  As previously shown, the expansion 
of CD8+ T cells in the absence of IL-2 signals was only modestly reduced.  However, we 
found that IL-2 selectively drives differentiation and survival of terminal effector 
phenotype CTL during the primary response to acute infection, and the entire difference 
in numbers during the effector phase could be attributed to the reduced formation of 
terminal CD8+ T cells in the absence of IL-2.   Memory precursor and long-lived memory 
CD8+ T cells were established normally in peripheral lymphoid organs in the absence of 
IL-2 signals.  Closer examination of memory CD8+ T cells in the spleen and peripheral 
tissues revealed a role for IL-2 in the differentiation of effector memory CD8+ T cells.   
 We also further analyzed the defective recall response of CD8+ T cells generated 
in the absence of IL-2 signals.  We found that in addition to failure of accumulation of 
secondary effector CD8+ T cells upon rechallenge, differentiation of secondary effector 
CTL to terminal effector phenotype was more severe than seen in the primary response.   
We conclude that IL-2 signals during the primary response allow entry into and survival 
within a CD8+ T cell effector differentiation program.  
Although reduced terminal effector phenotype CTL differentiation during the 
primary response is seen in the absence of IL-2 signals, this population is not completely 
absent.  Potential compensation for the lack of IL-2 signals by the closely related γc 
family member IL-15 is addressed in Chapter 3.  IL-2 and IL-15 are closely related 
cytokines, with receptors sharing two of three subunits, IL-2Rβ (CD122) and γc (CD132), 
which results in induction of signaling pathways shared by both cytokines [61].   
 Prior studies have suggested that IL-2 and IL-15 differentially regulate certain 
aspects of CD8+ memory T cell differentiation. While activation in the presence of high 
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levels of IL-2 in vitro preferentially promotes the subsequent in vivo development of 
effector and effector memory T cells, activation in the presence of IL-15 preferentially 
promotes central memory differentiation [62, 63]. Both of these cytokines have been 
used or proposed as potential immunotherapeutics. High-dose IL-2 treatment has been 
used clinically to treat several types of cancer, including renal cell carcinoma and 
melanoma, with modest effects on a subset of recipients [64-66]. The use of IL-15 has 
been suggested for boosting T and NK cell anti-tumor responses and as a vaccination 
adjuvant in various model systems [61, 67-72]. While IL-15 has a well-described role in 
promoting the homeostasis and survival of CD8+ memory T cells [73], differing mouse 
models of acute infection demonstrate either no role [74, 75] or a significant role[76] for 
IL-15 in the generation of effector CTL responses. In all, it remains unclear how and to 
what extent IL-2 and IL-15 mediate overlapping, differing or even opposing functions, 
particularly in the early phases of activation in which T cells enter into their 
differentiation program [3, 77]. 
We found that IL-15 does not drive the differentiation of terminal effector 
phenotype CD8+ T cells during the primary effector response in our model system. In 
addition, we found that IL-15 does not have a role in memory CD8+ T cell programming.  
Instead, we conclude that IL-15 is a survival signal for effector and memory CD8+ T cells 
after pathogen clearance.  These results indicate that even with a shared cytokine 
signaling apparatus, IL-2 signals in effector and memory CD8+ T cell programming are 
unique from those of IL-15.  
Chapter 4 addresses the molecular nature of the IL-2 signal as received by CD8+ 
T cells.  The mechanisms by which CD8+ T cells integrate environmental signals resulting 
in effector and memory fate decisions are not understood.   In this chapter, the 
JAK3/STAT5 pathway is tested for its role in driving CD8+ T cell fate decisions and 
programming of memory CD8+ T cells. 
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IL-2 induces several kinase pathways (JAK/STAT, PI3K, MAPK, as described 
above).  All of these pathways are capable of induction by signals received through other 
receptors during an immune response, at least to some degree.  However, the 
JAK3/STAT5 pathway is induced by γc cytokines alone, and of these, IL-2 is the most 
potent stimulant for JAK3/STAT5 activation during the effector CD8+ T cell response.  
For this reason, we chose to study the role of STAT5 in effector and memory CD8+ T cell 
differentiation, and in memory CD8+ T cell programming.  We found that unlike IL-2, 
STAT5 does not drive selective differentiation of a particular effector CD8+ T cell subset.  
Instead, STAT5 signals are broadly important for full accumulation of all effector CD8+ T 
cells and their effector function during the primary immune response.  After pathogen 
clearance, STAT5 signals are particularly important for the survival of terminal effector 
phenotype CTL and the establishment and maintenance of tissue residing memory CD8+ 
T cells.  Importantly, we found that IL-2 driven programming of memory CD8+ T cells is 
independent of STAT5, as STAT5 was not required for robust recall responses by 
memory CD8+ T cells.  This highlights different requirements for STAT5 mediated 
survival signals for primary and secondary effector CD8+ T cell responses and 
demonstrate that IL-2 dependent programming of memory CD8+ T cells is STAT5 
independent. 
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Introduction 
 Antigen-specific CD8+ T cells receive instructional signals during the primary 
phase of the immune response to acute infection that dictate later stages of 
differentiation. Upon antigen recognition, CD8+ T cells undergo massive clonal 
expansion and acquire effector functions that are critical for the elimination of 
intracellular pathogens, including cytolytic function and the ability to produce 
proinflammatory cytokines such as IFNγ and TNFα.   After the infection is resolved, most 
of the effector population dies, leaving behind a long- lived population of memory cells 
capable of rapid secondary protection upon re-exposure to the same or a related 
pathogen [1, 2]. 
 CD8+ memory T cell precursors can be identified among the effector population at 
the peak of the response to acute infection based on the expression of cell surface 
molecules such as IL-7Rα and KLRG1 [3, 4]. Intensive efforts are underway to 
understand the nature of the differentiation signals that differentially promote the 
emergence of effector cells that express high levels of KLRG1 and low levels of IL-7Rα 
(terminal effector phenotype CD8+ T cells), and memory precursor cells that express low 
levels of KLRG1 and high levels of IL-7Rα. CD4+ T cell-derived “help” is of particular 
importance in the generation of functional (capable of secondary responses to antigen) 
CD8+ memory T cells [5-9]. Other studies have suggested that memory potential may 
depend at least in part on asymmetric division at the initiation of the T cell response [10, 
11] or differential expression of the transcription factor T-bet driven by exposure to 
inflammatory cytokines such as IL-12 [3]. 
 Our recent studies have focused on the role of IL-2 in CD8+ memory T cell 
differentiation. Like others [12-14], we found that in the absence of IL-2 signals, CD8+ T 
cells showed only modest impairment in their ability to make robust primary responses 
following acute infection. However, IL-2 signals during the primary response were 
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required for the ability of the ensuing CD8+ memory cells to generate optimal secondary 
responses [15]. Several other observations indicated that the impact of IL-2 on CD8+ T 
cells impacted multiple differentiation pathways. For example, memory T cells generated 
in the absence of IL-2 skewed to a central memory-like phenotype as measured by 
expression of CD62L and the ability to produce IL-2 upon restimulation [15]. 
 We find that IL-2 plays a central role in the differentiation and survival of effector 
CTL that persist during the first few months after infection, as well as tissue- residing 
effector memory CTL. IL-2Rα-deficient CD8+ effector T cells responding to acute 
infection display robust cytokine production but modest decreases in CTL activity. Upon 
secondary challenge, IL-2Rα-deficient CD8+ memory T cells display a severe defect in 
their ability to differentiate into secondary effector CTL, maintaining an IL-7Rαhi 
CD62Lhi phenotype and a cytokine production profile typical of memory CTL, not 
effector CTL. 
Materials and methods 
Mice and infections 
 6 to 8 week old C57BL/6 (B6), B6.129S4-Il2ratm1Dw (IL-2Rα-deficient), B6.SJL-
PtprcaPepcb/BoyJ (B6.SJL, Ly5.1+) and B6.PL-Thy1a/CyJ (B6.PL, Thy1.1+) mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). WT and IL-2Rα- deficient P14 
TCR transgenic mouse colonies were maintained at the University of Utah. All animal 
experiments were conducted with the approval of the IACUC committee at the University 
of Utah. LCMV Armstrong 53b was grown in BHK cells and titered in Vero cells [16]. 
Mice were infected intraperitoneally (i.p.) with 2 x 105 plaque-forming units (PFU). 
Recombinant Listeria monocytogenes expressing the LCMV GP33-41 peptide (Lm-gp33, 
generated using described methods) was propagated in BHI broth and agar plates as 
previously described [17-19]. Prior to infection, the bacteria were grown to log phase and 
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concentration determined by measuring the O.D. at 600 nm (O.D. of 1 = 1 x 109 
CFU/ml). For secondary challenges, mice were injected intravenously (i.v.) with 2 x 105 
colony forming units (CFU). Recombinant vaccinia virus expressing the LCMV 
glycoprotein (VV- GP, provided by J.L. Whitton) was generated and propagated as 
described [20]. For secondary challenges, mice were injected i.p. with 2 x 106 PFU. 
Irradiation chimeras 
 To generate WT/IL-2Rα-deficient mixed bone marrow chimeras, recipient mice 
were given 900 rads using an analytical X-ray irradiator located in the mouse vivarium 
at the University of Utah. One day later, we harvested bone marrow from the femurs and 
tibias of WT and IL-2Rα-deficient donors. Following red blood cell lysis, bone marrow 
cells were incubated with biotinylated anti-CD3 antibodies (eBioscience, San Diego, CA), 
followed by incubation with anti-biotin magnetic beads (Miltenyi). CD3+ cells were 
depleted by passage through a magnetic column according to the manufacturer’s 
instructions (Miltenyi). CD3-depleted WT and IL-2Rα-deficient bone marrow cells were 
mixed 1:1 and injected i.v. into irradiated hosts. By using different combinations of 
congenic markers, we readily distinguished WT (Ly5.1+), IL-2Rα-deficient (Thy1.2+) and 
residual host (Thy1.1+) T cells in the periphery of host mice 8-10 weeks later. Similar 
methods were used to generate P14 irradiation chimeras. P14 irradiation chimeras were 
generated with a 1:1 mix of WT or IL-2Rα-deficient P14 bone marrow with B6 bone 
marrow. P14 were harvested a minimum of 8 weeks postirradiation. 
Cell suspensions and adoptive transfers  
 Splenocytes and lymph node cells were harvested at the indicated time points and 
re-suspended in RPMI 1640 supplemented with 10% FBS and antibiotics. Liver and lung 
lymphocytes were harvested by collagenase digestion as previously described [21]. 
Untouched CD8+P14 T cells were isolated from the spleens and lymph nodes of WT or 
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IL-2Rα-deficient P14 bone marrow chimeras by incubation with a biotinylated antibody 
cocktail followed by anti-biotin magnetic beads and depletion on a magnetic column, per 
manufacturer’s recommendations (Miltenyi). In addition, we added biotinylated CD44 
antibody (eBioscience, San Diego, CA) to eliminate CD44hi “memory phenotype” P14. 
TCR transgenic T cell purity was assessed by staining with CD44, Vα2 and Vβ8.1 
antibodies, followed by flow cytometric analysis. WT (Thy1.1+) and IL-2Rα-deficient 
(Thy1.1+Thy1.2+) P14 were mixed 1:1 and co-injected i.v. into naïve B6 (Thy1.2+) mice at 
the indicated doses one day prior to infection. 
Peptide restimulation and intracellular cytokine staining  
 Splenocytes were re- suspended in RPMI 1640 containing 10% fetal bovine serum 
and supplemented with antibiotics and L-glutamine. Mice were re-stimulated with 0.1 
µM H-2Db-restricted peptide (gp33-41) in the presence of Brefeldin A (1 µg/ml GolgiPlug). 
Cells were stained with cell surface antibodies, permeabilized and stained with cytokine 
antibodies (specific to IFNγ, TNFα and IL-2) using a kit per manufacturer’s instructions 
(BDBiosciences, Mountain View, CA). 
CTL assays  
 We utilized a FACS-based cytotoxicity assay as previously described [22]. EL4 cells 
were incubated with 0.1 µM gp33-41 peptide for 2 hours at 37° C.  Cells were washed and 
incubated with FACS-sorted WT or IL-2Rα-deficient P14 CTLs for two hours at 37° C at 
effector to target ratios ranging from 3:1 to 0.1:1. We stained for expression of Annexin V 
(BDBiosciences) and measured the percent of Annexin V+ target cells by FACS. Specific 
killing was determined by comparison to killing of unloaded control targets cells. 
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Tetramer staining and analysis  
 The H-2Db-restricted gp33-41 monomer was generated, biotinylated and 
tetramerized with streptavidin-conjugated allophycocyanin using described methods 
[23, 24], with modifications as described in protocols available on the NIH Tetramer 
Core Facility website (http://tetramer.yerkes.emory.edu/). Staining was performed at 
4°C for 1 hour in FACS buffer (PBS with 2% fetal bovine serum and .02% sodium azide). 
Antibodies and flow cytometry 
 Fluorescent dye-conjugated antibodies were purchased from eBioscience (San 
Diego, CA), BioLegend (San Diego, CA) or BDBiosciences (Mountain View, CA) with the 
following specificities: CD8, Thy1.1, Thy1.2, CD45.1, Vα2, Vβ8.1, CD44, IL-7Rα, KLRG1, 
CD27, CD62L, CXCR3, CD43, CD122, CD25, Eomes, T-bet, Granzyme B, CD107a, TNFα, 
IL-2 and IFNγ. Cell surface antibody staining was done in PBS containing 2% FBS, and 
intracellular cytokine staining was performed as described above. For T-bet and 
Granzyme B staining, cells were permeabilized using the same buffers as for intracellular 
cytokine staining (BDBiosciences, Mountain View, CA). For Eomes, cells were 
permeabilized and stained using the same buffers as those used for the anti-FoxP3 
antibody per the manufacturer’s instructions (eBioscience, San Diego, CA). For CD107a, 
the antibody was mixed with re-suspended cells during peptide restimulation prior to 
intracellular cytokine staining. Multi-parameter (6-7 color) analysis of antibody-stained 
cells was performed on a FACSCanto II flow cytometer (BDBiosciences, Mountain View, 
CA) and results analyzed using FlowJo software (TreeStar). Cell sorting was with on a 
FACSVantage (BDBiosciences, Mountain View, CA) at the University of Utah FACS core 
facility. 
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Microarray 
 RNA was isolated using RNeasy kits (Qiagen) from FACS-sorted P14 cells (day 8 
postinfection). Message was amplified and converted to Cy3 or Cy5-labeled cRNA using 
a commercially available kit per manufacturer’s instructions (Agilent Technologies). 
Four biological duplicates from each group were hybridized to Agilent whole mouse 
genome microarrays. For each of the four replicates, dual hybridization was performed 
using RNA obtained from WT and IL-2Rα-deficient P14 isolated from the same animal. 
Results were normalized and analyzed for differences in log2 expression values using 
GeneSifter software (Geospiza, Seattle, WA).  Microarray data has been submitted to the 
on-line depository GEO and conforms to all MIAME guidelines. 
Results 
Impaired accumulation and survival of CD8+ end stage  
effector T cells in the absence of IL-2 signals 
 Our previous studies found that in the absence of IL-2 signals, developing CD8+ 
memory T cells rapidly converted to a CD62Lhi phenotype [15]. To characterize this 
finding further, we analyzed the responses of LCMV-specific P14 TCR transgenic T cells 
either expressing or lacking the IL-2Rα. IL-2Rα-deficiency results in the loss of 
CD4+CD25+ regulatory T cell function and multi-organ autoimmunity at a young age [25-
27]. In order to mitigate non-specific effects this environment might have on T cell 
function, we sought to generate IL-2Rα-deficient P14 donors that lacked autoimmune 
side effects. We generated mixed bone marrow chimeras by transferring a 1:1 mix of 
wildtype (WT) B6 and either WT or IL-2Rα-deficient P14 bone marrow (BM) into 
lethally irradiated B6 hosts, as previously described [15]. Because the WT BM gave rise 
to a functional regulatory T cell population, the chimeras remained healthy with no signs 
of autoimmunity. Naïve (CD44lo) WT and IL-2Rα-deficient P14 cells were harvested from 
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the chimeras and co-transferred into naïve B6 hosts, followed by LCMV infection. 
Because of their variable expression of Thy1 alleles, we simultaneously tracked WT P14 
(Thy1.1+) and IL-2Rα-deficient P14 (Thy1.1+Thy1.2+) responses in B6 hosts (Thy1.2+) at 
various time points postinfection. 
 As previously observed [15], WT P14 responders expanded modestly (2-3-fold) 
better than IL-2Rα-deficient P14 responders by the peak of the response. Both 
populations also formed memory populations that persisted at stable levels throughout 
the course of our experiments (Fig. 2.1A). However, a slightly higher fraction of IL-2Rα-
deficient P14 cells was lost during the contraction phase, as compared to the peak of the 
response (Fig. 2.1B).  To determine the cause of this loss, we analyzed the differentiation 
of effector cell and memory precursor populations at the peak of the response and in the 
transition to memory. Recent studies have found that terminal effector phenotype CTL 
can be differentiated from memory precursor/memory cells based on variable expression 
of IL-7Rα and KLRG1 [3]. At the peak of the primary response (day 8), we observed 2-3-
fold fewer KLRG1hiIL7Rαlo effector CTL among the IL-2Rα-deficient P14 responders, as 
compared to WT P14. WT P14 formed a population of detectable KLRG1hi terminal 
effector phenotype CTL that slowly faded from the memory pool over the course of 4-6 
months (referred to here as short-term effector memory cells). In contrast, IL-2Rα-
deficient effector cells disappeared rapidly, comprising 10-20-fold lower levels in the 
spleen at day 42 postinfection (Fig. 2.2). WT and IL-2Rα-deficient P14 demonstrated no 
differences in the generation of KLRG1loIL7Rαhi memory precursors at the peak of the 
response (day 8 postinfection). Numerical differences in the number of WT and IL-2Rα-
deficient P14 could almost entirely be ascribed to deficiencies in the generation of 
terminal effector phenotype cells. Several other markers also confirmed the rapid 
disappearance of effector cells in the IL-2Rα-deficient P14 population. Besides their 
expression patterns of KLRG1 and IL-7Rα, differentiated effector populations were  
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Figure 2.1 The magnitude of the CD8+ T cell response is modestly reduced in the 
absence of IL-2.  Naïve (CD44-lo) WT and IL-2Rα-/- (KO) P14 were harvested from the 
spleens and lymph nodes of P14 BM Chimeras, mixed 1:1, and coinjected into naïve B6 
mice 1 day prior to LCMV infection.  A) The graphs display the total number of WT and 
IL-2Rα-/- P14 harvested from the spleen at indicated time points.  B) The fraction of 
surviving P14 cells within each group as compared with the peak response (day 8).  Error 
bars indicate the SEM (n=3-4 per time point, statistical significance determined by 
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Figure 2.2 IL-2 drives the differentiation and survival of terminal effector phenotype and 
effector memory CD8+ T cells.  Naïve (CD44-lo) WT and IL-2Rα-/- (KO) P14 were 
harvested from the spleens and lymph nodes of P14 BM Chimeras, mixed 1:1, and 
coinjected into naïve B6 mice 1 day prior to LCMV infection. A) Representative flow plots 
display the frequency of terminal effector phenotype P14 (KLRG1-hi, IL7Rα-lo) and 
memory precursor/memory P14 (KLRG1-lo, IL7Rα-hi) at the indicated time points post 
infection.  B) Graphs show the total number of end-stage effector P14 (KLRG1-hi, IL7Rα-
lo) at the indicated time points postinfection. Error bars indicate the SEM (n=3-4 per 
time point).  Results are representative of 5-6 independent experiments.  
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CD27lo, CD62Llo, CXCR3lo and CD43lo.  Effector cells bearing these characteristics also 
disappeared rapidly in the absence of IL-2 signals in both the spleen and liver (Fig. 2.3 
and Fig. 2.4). 
Lack of IL-2 signals adversely impacts the function 
of effector CTLs 
 Because we observed modest but reproducible differences in the number of CD8+ 
effector CTL at the peak of the response in the absence of IL-2 signals, we tested the 
hypothesis that IL-2 might also be important for optimal effector function. Previous 
studies in which CTL received little or no IL-2 signals were disrupted during in vitro 
activation followed by in vivo adoptive transfer suggested that IL-2 might play an 
important role in the development of effector function [28]. We focused on a time point 
at which the high affinity IL-2 receptor was expressed at high levels (day 5) as well as the 
peak of the effector response (day 8), at which time the high affinity IL-2R was no longer 
expressed (Fig. 2.5A). 
 Initially, we measured intracellular expression of the transcription factors T-bet 
and Eomes. These related T-box transcription factors have been implicated in the 
differentiation of effector T cells and in the acquisition of effector T cell function, such as 
IFNγ production and CTL activity, as well as in the differentiation of functionally and 
phenotypically normal CD8+ memory T cells [3, 22, 29, 30]. We found no differences in 
expression of T-bet at either day 5 or day 8 postinfection. Conversely, IL-2Rα-deficient 
P14 demonstrated a reproducible 2-fold increase in the amount of Eomes at day 8 
postinfection (Fig. 2.5A). These differences were not due to differences in the 
composition of each population, as direct comparison of end-stage effector and memory 
precursor populations revealed the same 2-fold disparity in Eomes expression (data not 
shown). While these differences are modest, they remain of interest given that similar  
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Figure 2.3 Terminal effector phenotype and effector memory CD8+ T cell differentiation 
and survival in the spleen is impaired in the absence of IL-2. Representative flow plots 
display cell surface expression of the indicated molecules by WT and IL-2Rα-/- (ko) P14 




















































































































































































































































































































































































































































































































































Supplemental Figure 1. Short-lived effector/short-lived effector memory 
differentiation and survival in the spleen is impaired in the absence of IL-2.  
Representative flow plots display cell surface expression of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the spleen at various time 




















































































































































































































































































































































































































































































































































Su plemental Figure 1. Short-lived effector/short-lived effector memory 
differentiation and survival in the spl en is impaired in the absence of IL-2.  
Representative flow plots display cell surface expre sion of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the spl en at various time 




















































































































































































































































































































































































































































































































































Supplemen al Figure 1. Short-lived effector/short-lived effector memory 
differentiation and survival in the spleen is impaired in the absence of IL-2.  
Representative flow plots display cell surface expression of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the spleen at various time 
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Supplemental Figure 1. Short-lived effector/short-lived effector memory 
differentiation and survival in the spleen is impaired in the absence of IL-2.  
Representative flow plots display cell surface expression of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the spleen at various time 




















































































































































































































































































































































































































































































































































l t l i r  . hort-lived e fector/short-lived e fector e ory 
i ti ti   r ival in the spl en is i paired in the absence of IL-2.  
t ti  fl  l ts display cell surfac  expre sion of the indicated 
l l     I -2 -def cient (ko) P14 in the spl en at various ti e 








































































































































































































































































































































































































































































































































Supplemental Figure 1. Short-lived eff ctor/short-lived effector memory 
differentiatio  nd s rvival in the spleen is impaired n th  absenc  of IL-2.  
Repr sen ative flow plots display cell surface exp ssion of the i dicated 
molecul s by WT and IL-2Rα-defi i nt (ko) P14 in the spleen at various time 








































































































































































































































































































































































































































































































































Su plemental Figure 1. Short-lived effector/short-lived effector memory 
differ ntiation and survival in he spl n is impaired in th  absenc  f IL-2.  
R pr sentative flow plots d splay c ll surface expre sion of th  indicated
mol cul s by WT and IL-2Rα-defi i nt (ko) P14 in the spl en at various time 

























































































































































































































































































































































































































































































u le t l i r  . rt-li  ff t r/ rt-li  ff t r r  
differ nti ti   r i l i  t  l  i  i ir  i  t   f I - .  
epr s t ti  fl  l t  i l  ell rf  r i  f t  i i t  
ol cules    I - - fi ie t ( )  i  t  l  t ri  ti  




















































































































































































































































































































































































































































































































































Supplemental Figure 1. Short-lived effector/short-lived effector memory 
differentiatio  nd survival in the spleen is impaired in the absence of IL-2.  
Repr sent tive flow plots display cell surface expr ssion of the indicated 
mol cules by WT and IL-2Rα-deficient (ko) P14 in the spleen at various time 



















































































































































































































































































































































































































































































































































Su plemental Figure 1. Short-lived effector/short-lived effector memory 
differentiation and survival in the sple n is impaired in th  absence of IL-2.  
Repr sentative flow plots d splay cell surface expression of th  indicated 
molecul s by WT and IL-2Rα-defi i nt (ko) P14 in the spleen at various time 
























































































































































































































































































































































































































































































Su ple ental Figure 1. Short-lived effector/short-lived effector e ory 
differentiation and sur ival in the spl n is i paired in th  absence of IL-2.  
Repr sentative flow plots display cell surface expre sion of the indicated 
olecul s by T and IL-2Rα-defi i nt (ko) P14 in the spl en at various ti e 



















































































































































































































































































































































































































































































































































Supplemental Figure 1. Short-liv d ffector/short-lived ffector memory 
differentiation nd s rvival in the spl n i  impaire in th  absence of IL-2.  
Re s n ative flow plots display c ll surface exp ssion of th i dicated 
molecules by WT and IL-2Rα-defi i nt (ko) P14 in the spl en at vari us time










































































































































































































































































































































































































































































































































Su plemental Figure 1. Short-lived effector/short-lived effector memory 
diffe ntiation and sur ival in the spl n is imp ired in th  absence of IL-2.  
R sen ative flow plots disp ay c ll surface expre sion of h indicated
mol cules by WT and IL-2Rα-d fi i t (ko) P14 in the spl en at various time 





































































































































































































































































































































































































































































































































l t l i r  . rt-li  ff t r/ rt-li  ff t r r  
iff r ti ti  rvi l i   l  i  i air  i  t   f I - .  
re t ti fl  l t l  ll rf  r i   t  i i t
l l     I - - fi ient ( )  i  t  l  t ri ti  
oi t  t-i f cti  it  . 
2 3 4 5














































































































































































































































































































































































































































































e  r  
i e   f I - .  
 i i t  


































































































































































































































































































































































































































































































































s lived effector e ory 
iff i d in th  absenc  of IL-2.  
x e sion o  h  indicated 





























































































































































































































































































































































































































































Su ple ental Figu e 1. S o t lived effecto / ho t li  ff t  r  
differ ntiation and sur ival in the spl n is i p i e  i  t   f I - .  
Rep esenta ive flow plots display cell su face e p i  f t e i i t
molecules by T and IL-2Rα-defici t (ko) P14 in t  s l  t v rio s tim  




























































































































































































































































































































































































































































































































































Supple ental Figure 1. Short-lived effector/short-lived effector e ory 
diffe ntiation and survival in the sple n is i paired in th  abs nce of IL-2.  
Rep sen ative flow plots d splay cell surface expression of th  indicated 
l cules by T a d IL-2 α-defi ient (ko) P14 in the spleen at various ti e 
points po t-infection ith L V. 
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Figure 2.4 Terminal effector phenotype and effector memory CD8+ T cell differentiation 
and survival in the liver is impaired in the absence of IL-2. Representative flow plots 
display cell surface expression of the indicated molecules by WT and IL-2Rα-/- (ko) P14 


































































































































































































































































































































































































































































































































































































































































































































Supplemental Figure 2. Short-lived effector/short-lived effector memory 
differentiation and survival in the liver is impaired in the absence of IL-2. 
Representative flow plots display cell surface expression of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the liver at various time 






























































































































































































































































































































































































































































































































































































































































































































Supplemental Figure 2. Short-lived effector/short-lived effector memory 
differentiation and survival in the liver is impaired in the absence of IL-2. 
Representative flow plots display cell surface expression of the indicated 
molecules by WT and IL-2Rα-deficient (ko) P14 in the liver at various time 
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l ntal Figure 2. Short-lived effector/short-lived effector e ory 
iff r ti ti n and survival in the liver is i paired in the absence of IL-2. 
r s t tive flow plots display cell surface expression of the indicated 
l c l s y T and IL-2Rα-deficient (ko) P14 in the liver at various time 
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le e tal i re 2. hort-lived effector/short-lived effector e ory 
differentiation and survival in the liver is i paired in the absence of IL-2. 
epresentative flo  plots display cell surface expression of the indicated 
olecules by  and IL-2 -deficient (ko) 14 in the liver at various ti e 
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Suppl nt l Figu  S
differentiation and u i al in he li e i i pai ed in he ab en e o L 2
Representative flow plots display cell su ace exp ession o he indica ed
olecules by T and IL 2 α de icien ko P14 in he live a va ious i e
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Suppl nt l Figure 2. Short-lived effector/short-lived effector e ory 
differentiation and survival in the liver is i paired in the absence of IL-2. 
Representative flow plots display cell surface expression of the indicated 
olecules by T and IL-2 α-deficient (ko) P14 in the liver at various ti e 
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Figure 2.5 IL-2Rα-deficient P14 CTLs have modestly decreased cytolytic activity. Effector 
WT and IL-2Rα-/- P14 were assessed for expression of effector molecules and function.  
A) WT (black line) and IL-2Rα-/- (gray line) P14 were tested for cell surface expression 
of CD25 and intracellular expression of T-bet, Eomes and Granzyme B on days 5 and 8 
postinfection, as indicated.  Gray filled histograms are isotype controls.  B) We assessed 
production IFNγ, TNFα and IL-2 by WT and IL-2Rα-/- P14 as indicated in 
representative plots following 4 hour ex vivo restimulation with gp33-41 peptide in the 
presence of Brefeldin A.  C) Representative flow plots indicate CD107a surface 
expression as a measure of degranulation during a 4 hour ex vivo gp33-41 restimulation of 
WT and IL-2Rα-/- P14 at day 8 postinfection with LCMV.  D) gp33-41 peptide loaded EL4 
cells were incubated with WT or IL-2Rα-/- P14 CTL FACS-sorted from spleens at day 8 
postinfection.  CTL induced apoptosis was measured by staining with Annexin V 2 hours 
later.  Error bars represent the SEM (n=3-4/group) and differences between WT and IL-
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Supplemental Figure 3. IL-2Rα-deficient CTLs degranulate efficiently upon 
restimulation.  Representative flow plots indicate CD107a surface expression 
as a measure of degranulation during a 4 hour restimulation of WT and 









































unstim +gp33 peptide 
WT P14 
KO P14 
Supplemental Figure 3. IL-2Rα-deficient CTLs degranulate efficiently upon 
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unstim +gp33 peptide 
WT P14 
KO P14 
Supplemental Figure 3. IL-2Rα-deficient CTLs degranulate efficiently upon 
restimulation.  Representative flow plots indicate CD107a surface expression 
as a measure of degranulation during a 4 hour restimulation of WT and 
IL-2Rα-deficient (ko) P14 CTL at day 8 post-infection with LCMV. 
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differences in Eomes expression in mice with a single functional allele impacts CD8+ T 
cell differentiation and effector function [29]. Nevertheless, these results are inconsistent  
with an obligate role for IL-2 in the acquisition of effector function, given that Eomes 
expression was higher in the absence of IL-2. Furthermore, they suggest that Eomes 
expression is influenced indirectly by IL-2, as no expression differences were seen at day 
5 when WT P14 responders are still actively receiving IL-2 signals. 
IL-2Rα-deficient CTL expressed Granzyme B and de-granulated and produced 
cytokines upon re-stimulation (Fig. 2.5A, B, C). However, IL-2Rα-deficient CTL 
demonstrated a modest decrease in CTL activity at day 8 postinfection (Fig. 2.5D). To 
assess effector CTL development at this time point, we analyzed RNA expression by WT 
and IL-2Rα- deficient P14 CTL by microarray. We observed significant up-regulation of 
effector molecules involved in cytolysis and effector differentiation in WT CTL, including 
Granzymes and Perforin, as well as an increase in T-bet (Table 2.1). While Blimp-1 was 
not significantly up-regulated in WT cells, Bcl-6 was significantly up-regulated in IL-
2Rα- deficient CTL (Table 2.2). Because Blimp-1, which has recently been shown to 
promote effector and memory CTL differentiation [31, 32], is a potential repressor of Bcl-
6 expression in T cells [33], this finding leaves open the possibility that its 
transcriptional activity is posttranscriptionally or posttranslationally reduced in the 
absence of IL-2 signals, despite no changes in mRNA expression. A variety of NK 
receptors, likely indicators of CTL differentiation [3], also demonstrate increased 
expression in WT CTL. IL- 2Rα-deficient CTL expressed higher levels of IL-2 and TNFα 
as well as receptors that mediate trafficking to and within secondary lymphoid organs 
(CCR7 and CXCR5)(Table 2.2). These findings were predicted by cell surface staining 
and again indicate a skewing away from a differentiated effector phenotype. While we 
observed differences in expression of several pro and antiapoptotic mediators, no clear 
pattern emerged to explain the failure of IL-2Rα-deficient effector CTL to survive  
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Table 2.1 Genes with increased expression in WT P14 compared to IL-2Rα-/- P14 on day 
8 postinfection with LCMV. All fold differences are significant (p<0.05, n=4 per group) 
(*no significant difference).  diff, differentiation 
 
 
Name fold up WT function 
Granzyme A 3.3 cytotoxicity 
Granzyme B 1.8 cytotoxicity 
Granzyme E 2.4 cytotoxicity 
Perforin 1.4 cytotoxicity 
Klre1 1.9 NK/CTL diff. marker 
Klrb1b 2.3 NK/CTL diff. marker 
Klrk1 1.7 NK/CTL diff. marker 
Klrg1* 1.2 NK/CTL diff. marker 
Klrc2 1.5 NK/CTL diff. marker 
Klra3 1.5 NK/CTL diff. marker 
Klra7 1.8 NK/CTL diff. marker 
2B4 1.7 NK/CTL diff. marker 
IL12Rb2 1.5 cytokine receptor 
Tbet 1.5 CTL differentiation 
Blimp-1* 1.2 CTL differentiation 
Cdca2 1.5 cell cycle 
Ki-67 1.5 cell cycle 
Cdc25b 1.6 cell cycle 
Cyclin A2 1.7 cell cycle 
Cdc451 1.7 cell cycle 
Cdc7 1.8 cell cycle 
Gspt2 1.8 cell cycle 
Cdca5 1.8 cell cycle 
Cdc23 1.9 cell cycle 
Rb1 1.8 cell cycle arrest 
Cdkn1a 1.9 cell cycle arrest 
Bcl-XL 1.5 survival 
FasL 1.5 apoptosis 
Caspase 3 1.6 apoptosis/proliferation 
c-Flip 1.6 apoptosis/proliferation 
RIP-1 1.6 apoptosis/proliferation 
Faf-1 1.5 apoptosis 
Jak-1 1.6 Cytokine signaling 
NFAT4 1.7 Transcription Factor 
PLCγ-1 1.7 TCR signaling 
Socs2 3.7 Neg. regulation of JAK/STAT 	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Table 2.2 Genes with increased expression in IL-2Rα-/- (KO) P14 compared to WT P14 








Bcl6 1.9 memory differentiation 
IL-2 2.3 cytokine 
TNFa 1.5 cytokine 
IL-10 1.9 cytokine 
IL-17F 1.7 cytokine 
CXCR5 5.4 SLO trafficking 
CCR7 3.3 SLO trafficking 
CTLA4 1.5 neg. costimulation 
CD40 2.7 costimulation 
CD44 1.6 activation marker 
TCF-1 2.2 CTL diff. arrest 
LEF-1 1.3 CTL diff. arrest 
Bcl2 1.8 Survival 
Fas 2.1 apoptosis 
Bim 1.7 apoptosis 
Egr1 2.3 induction of NFAT 
Egr4 3.5 induction of NFAT 
c-jun 1.8 gene activation 
Xcl1 2.7 T cell/DC interactions 
CD30L 3.5 activation 
CD9 2.2 adhesion 
GATA-2 1.6 fate determination 	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following antigen clearance. However, WT P14 CTL demonstrated enhanced expression 
of a variety of cell cycle participants, indicating that IL-2 may drive cell division later in 
the primary response (Table 2.1). This finding corresponds to previous observations by 
others [13, 34] and our own finding that WT responders demonstrate enhanced 
expansion between days 5 and 8 postinfection [15].  Overall, while many of the gene 
expression differences are individually modest, they collectively support a role for IL-2 in 
driving the differentiation and enhancing the function of primary CTL. One possible 
interpretation of these results is that differences in cytolytic function (Fig. 2.5D) and 
expression of CTL differentiation markers and cytolytic molecules (Table 2.1) reflect 
differences in the generation of terminal effector phenotype CTL in the absence of IL-2 
(Fig. 2.2), and future studies will be needed to directly compare the differentiation status 
of purified terminal effector phenotype and memory precursor CD8+ cell populations in 
the presence or absence of IL-2 signals. 
Poor differentiation of secondary effector T cells 
in the absence of IL-2 
 Because CD8+ memory T cells generated in the absence of IL-2 signals mount poor 
secondary responses, we assessed their ability to become secondary effector cells. To 
assess polyclonal endogenous recall responses, we generated mixed bone marrow 
chimeras using a 1:1 mix of bone marrow from WT and IL-2Rα-deficient donors. At 8-10 
weeks posttransplant, mice were challenged with LCMV. As measured by MHC Class I 
tetramers (Fig. 2.6A) and the frequency of IFNγ producing cells following peptide 
restimulation, even in the absence of IL-2 signals CD8+ T cells generated robust primary 
responses and long-lived memory populations similar to that of wildtype responders. 
Mice were rechallenged with either a recombinant Listeria monocytogenes expressing 
the LCMV glycoprotein (Lm-gp33) or a recombinant vaccinia virus expressing the LCMV  
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Figure 2.6 IL-2Rα-deficient memory CD8+ T cells fail to accumulate upon secondary 
challenge.  A) We generated mixed BM chimeras using WT and IL-2Rα-/- donor BM 
cells in equal number.  At 10 weeks post transplant, we infected chimeras with LCMV 
and assessed CD8+ T cell responses in the spleen using Db-gp33-41 tetramer at the peak 
of the primary response (day 8 postinfection), during memory maintenance (day 150 
postinfection), or at the peak of the secondary response (day 5 post rechallenge with Lm-
gp33 or VV-gp).  The bar graph indicates the ratio of WT and IL-2Rα-/- tetramer-
binding responders at the indicated time points.  B) WT and IL-2Rα-/- P14 (500 of each) 
were co-transferred into B6 mice, followed by infection with LCMV one day later. WT 
and IL-2Rα-/- memory P14 cells (>300 days postinfection) were FACS-purified from the 
spleen and transferred separately (10,000 of each) into naïve B6 hosts. Secondary hosts 
were challenged with LCMV and recall responses assessed in the spleen 7 days later.  
Flow plots show the frequency of WT or IL-2Rα-/- P14 at the peak of rechallenge, and 
bar graphs indicate the fold expansion.  Results are representative of 3-4 separate 
experiments.  Error bars indicate the SEM (n=3-4/group), and differences in fold 































































































Supplemental Figure 4. IL-2Rα-deficient CD8+ memory T cells fail to 
generate robust recall responses upon secondary challenge in the absence of 
competing WT memory cells.  WT and IL-2Rα-deficient P14 (5 x 102 of each) 
were co-transferred into B6 mice, followed by infection with LCMV one day 
later.  WT and IL-2Rα-deficient memory P14 cells (>300 days post-infection) 
were FACS-purified from th  spleen and transferred separately (1 x 104 of 
each) into naïve B6 hosts.  Secondary hosts were challenged with LCMV and 
recall responses assessed in the spleen 7 days later.  Results are 
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glycoprotein (VV-GP) at 150 days postinfection. As previously observed [15], IL-2Rα- 
deficient CD8+ memory T cells demonstrated a 10-15-fold deficit in their ability to 
generate secondary responses, as compared to WT.   Furthermore, poor recall responses 
were not due to competition with WT memory CTL.  Similar differences were seen when 
FACS-purified WT and IL-2Ra-deficient memory P14 were transferred into separate 
naïve B6 hosts prior to rechallenge (Fig 2.6B).   
 A closer analysis of the tetramer binding cells at the peak (day 5) of the secondary 
response revealed that IL-2 signals were required for the generation of secondary 
effector CTL (KLRG1hiIL-7Rαlo) (Fig. 2.7A, C). Furthermore, secondary responders 
induced in the absence of IL-2 remained CD62Lhi (Fig. 2.7A), CD27hi and CXCR3hi (Fig. 
2.7B), all characteristics of memory cells, not effector cells. These defects were present 
but modest at the peak of the primary response and greatly exacerbated upon secondary 
challenge (Fig. 2.7A,B). To assess function, we restimulated splenocytes ex vivo both 
before and after rechallenge. Prior to rechallenge, both wildtype and IL-2Rα-deficient 
memory populations primarily consisted of cells capable of simultaneously producing 
IFNγ and TNFα (double producers), or IFNγ, TNFα and IL-2 (triple producers), with few 
cells only able to produce IFNγ (single producers). Following rechallenge and the 
development of secondary effectors, the cytokine-producing profile of WT responders 
shifted dramatically towards single or double producers, with few triple producers. 
Conversely, the cytokine-producing profile of IL-2Rα-deficient secondary responders 
was largely unchanged, again reflecting an inability to generate large numbers of 
secondary effector CTL (Fig. 2.7D). 
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Figure 2.7 IL-2Rα-deficient CD8+ memory T cells fail to differentiate into secondary 
effector CTLs upon rechallenge.  WT and IL2Rα-/- Bone Marrow chimeras were 
generated, infected, and rechallenged as described in Figure 2.6.  A) Representative flow 
plots, gated on tetramer binding CD8+ T cells, indicate the frequency of terminal effector 
phenotype (KLRG1-hi, IL7Rα-lo, or CD62L-lo) cells among WT or IL-2Rα-/-(KO) 
responders at the indicated time points.  B) Representative flow plots show CXCR3 and 
CD27 expression at the indicated time points.  C) The bar graphs indicate the ratio of WT 
to IL-2Rα-/- tetramer binding CD8+ T cells that display a KLRG1-hi, IL7Rα-lo terminal 
effector phenotype at the peak of the primary or secondary response with the indicated 
infections.  Error bars indicate the SEM (n=3-4/group, p<0.05 when comparing ratios at 
primary or secondary response).  D) After 4 hours of ex vivo gp33-41 peptide 
restimulation of splenocytes, we assessed the ability of WT and IL-2Rα-/- responders to 


































































































































































































Supplemental Figure 5. IL-2Rα-deficient CD8+ memory T cells fail to 
differentiate into secondary effector CTL following secondary challenge.  
Representative flow plots display cell surface expression of CXCR3 and CD27 
by WT or IL-2Rα-deficient Db/GP33-41 tetramer-binding cells 8 days after 
primary challenge with LCMV or 5 days after secondary challenge of day 150 
LCMV immune mice with Lm-gp33.   
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IL-2 promotes the differentiation of CD8+ 
effector memory T cells 
 Our prior studies confirmed that CD8+ memory T cells generated in the absence of  
IL-2 signals quickly converted to a CD62Lhi central memory phenotype [15]. However,  
because in the present study we observed in the absence of IL-2 signals a rapid loss of  
KLRG1hiIL-7Rαlo effector cells that are also CD62Llo, we considered the possibility that 
our prior observations simply reflected a loss of this population and not a role for IL-2 in 
the generation of bona fide effector memory T cells. To test this possibility we assessed 
CD62L expression by IL-7Rαhi memory T cells as a measure of true effector memory T 
cell differentiation and survival. We found that even this population demonstrated a 
rapid loss of CD62Llo effector memory T cells in the spleen following acute LCMV 
infection in the absence of IL-2 signals (Fig. 2.8A). Furthermore, we found that WT 
tissue-residing memory P14 in the liver demonstrated a selective advantage over time as 
compared to IL-2Rα-deficient memory P14. This survival advantage was intermediate in 
the spleen and not observed in the lymph nodes (Fig. 2.8B, C). We therefore concluded 
that IL-2 played a central role in the differentiation of effector memory T cells in both the 
spleen and peripheral sites of infection. 
 In all, these data indicate that IL-2 influences a wide spectrum of effector 
differentiation, from end-stage effector cells at the peak of the response to both short 
lived and long lived effector memory CTL in secondary lymphoid tissues and peripheral 
sites of infection.  Numerically, the differentiation of central memory T cells appears to 
be independent of IL-2, as we observe roughly similar numbers of central memory 
phenotype WT and IL-2Rα-deficient CTL at early memory points (data not shown). 
Because IL-2Rα-deficient memory CTL at early memory time points are largely central 
memory phenotype already, the overall number of central memory cells remains stable  




Figure 2.8 IL-2 drives the differentiation of long lived tissue residing effector memory 
CTLs.  We transferred 500 WT and IL-2Rα-/- P14 cells prior to LCMV infection.  A) 
Representative flow plots indicate the frequency of central memory (CD62L-hi) 
phenotype cells in the spleen at the indicated time points after LCMV infection.  All plots 
are gated on the memory precursor/memory population (KLRG1-lo, IL-7Ra-hi).  B) 
Representative flow plots indicate the relative frequencies of WT and IL-2Rα-/- P14 (ko) 
in the spleen, mesenteric lymph nodes (MLN) and liver at days 8 and 42 postinfection.  
C) The bar graph displays the ratio of WT to IL-Rα-/- responders at day 8 (effector) and 
day 42 (memory) postinfection with LCMV in the indicated tissues.  Error bars indicate 
the SEM (n=3) and the results are representative of four separate experiments.  The ratio 
increase in the liver at day 42 is statistically significant as compared to the spleen and 
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throughout memory maintenance.  On the other hand, at early memory time points the 
WT memory population is largely composed of short-term and long-term effector 
memory cells.  Over time, the memory population remains stable but eventually converts 
to a central memory phenotype, whether due to conversion of existing effector memory  
cells to central memory cells [32]or replacement of effector memory cells with central 
memory cells due to homeostatic mechanisms[33].  While the end result at late memory  
time points is a 3-fold difference in the number of central memory cells (Fig. 2.1), our 
results suggest that IL-2 mainly plays a role in effector and effector memory CTL 
differentiation and that the defect in central memory cells is more precisely one of 
secondary effector differentiation. 
Discussion 
Our understanding of the role of IL-2 during in vivo immune responses has 
undergone changes and revisions over the years. Although it was originally thought to be 
required for T cell expansion, we find robust CD8+ T cell expansion even in the complete 
absence of high affinity IL-2 signals. However, our findings suggest that IL-2 plays a 
unique and important role as a fate determination and differentiation signal for activated 
T cells in vivo. Here again, the role of IL-2 is complex. While IL-2 plays a role in 
promoting the emergence and function of effector CTLs during the primary response, its 
impact is particularly pronounced in the rapid disappearance of this population during 
the contraction phase. Expression of the high affinity IL-2 receptor generally 
corresponds with bursts of IL-2 production in vivo, with the notable exception of the 
regulatory T cell subset. We observe little to no expression of IL-2Rα at day 8 
postinfection or beyond, indicating that the high affinity IL-2R signal is confined to the 
primary T cell response and expansion phase. We therefore conclude that IL-2 signals 
during priming influence the generation of effector CTL during primary expansion but 
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more particularly their persistence once the virus is cleared. These findings are 
consistent with previous results demonstrating that IL- 2 signals during the first week of 
infection promote the subsequent survival of IL-7Rαlo and CD62Llo responders during 
the contraction phase [15]. Two recent reports have also demonstrated a role for IL-2 in 
driving effector CTL differentiation.  These studies found that effector CTL 
differentiation was influenced by the concentration of IL-2 following activation[35] or by 
the length of time activated CTLs were able to incorporate high affinity IL-2 signals [36]. 
Together with our current report, these studies demonstrate a nonredundant role for IL-
2 in enhancing effector CTL differentiation, survival and function.  Our report further 
demonstrates that in the complete absence of high affinity IL-2 signals, secondary 
effector CTL differentiation is dramatically impaired.  One intriguing possibility is that 
while strong IL-2 signals enhance effector differentiation, some IL-2 signals are required 
in order for memory precursor effector cells to maintain, perhaps through epigenetic 
changes, their ability to access the effector differentiation transcriptional program.  Thus 
memory cells generated in the absence of IL-2 signals would be largely unable to enter 
an effector differentiation pathway upon reactivation.  Future studies are needed to 
identify epigenetic changes as well as changes in transcriptional activity that are 
influenced by IL-2 signals in differentiating CTL in vivo. 
 Of particular interest is our finding that the generation and/or survival of 
secondary effector CTL is largely disabled in the absence of IL-2 signals. Our prior 
findings have demonstrated that IL-2Rα-deficient CD8+ memory T cells divide rapidly 
upon rechallenge but fail to accumulate as compared to wildtype memory cells [15]. We 
find here that despite their rapid division, almost no secondary effector CTL emerge in 
the absence of IL- 2 signals. While there is some evidence of effector differentiation, 
including up-regulation of KLRG1, secondary effector cells rapidly disappear from the 
response, suggesting that IL-2 provides a differentiation signal to activated T cells that 
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enables or potentiates entry into an effector/effector memory lineage. Prior studies have 
shown that secondary effector and memory T cells skew more strongly to the effector 
and/or effector memory lineage, maintaining low levels of CD62L over long periods of 
time as compared to primary memory T cells[37]. 
We propose that IL-2 provides a differentiation signal that enables entry into and 
survival within the effector “program”. This may include epigenetic imprinting during 
the primary response that enable or potentiate effector differentiation upon subsequent 
encounters with antigen. Because CD8+ memory T cells are prone to become highly 
differentiated secondary effector/effector memory cells upon secondary activation, the 
absence of an IL-2 driven effector differentiation signal during the primary response may 
specifically and adversely impact the generation of highly differentiated secondary 
effector CTL. In this sense, IL-2 may be most appropriately described as an effector 
differentiation factor rather than a memory differentiation factor. While it may not be 
required for the selection of memory populations during the primary response, its role in 
driving effector differentiation is a key step in conferring the ability of memory T cells 
that do emerge to differentiate into effector cells upon secondary engagement with 
antigen. 
 The molecular and transcriptional nature of the IL-2-driven effector differentiation 
program remains unknown. Several transcription factors have been implicated in the 
differentiation of CD8+ effector T cells. Of particular interest are the Tbox transcription 
factors T-bet and Eomesodermin (Eomes). T-bet and Eomes drive effector 
differentiation and are regulated in response to inflammatory signals such as IL-12 or 
Type I IFNs [3, 37, 38]. Eomes impacts the differentiation and survival of CD8+ effector 
T cells by influencing the expression of effector molecules such as IFNγ and CD122 [29]. 
Another molecule of interest is the transcriptional repressor Blimp-1. While past studies 
have focused on the role of Blimp-1 in plasma cell differentiation, recent studies suggest 
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an important role for this molecule in CD8+ effector differentiation [39, 40] during acute 
viral infection and CD8+ T cell exhaustion [41] during chronic viral infection.  Blimp-1 
induction during in vitro T cell activation is dependent on IL-2 and forms a feedback 
loop to inhibit IL-2 production[42]. Additionally, similar to responding CD8 T cells that 
do not receive IL-2 signals, Blimp- 1 deficient CD8+ T cells also show a defect in effector 
and effector memory differentiation following acute infection [39, 40], as well as a 
reduced ability of Blimp-1 deficient memory cells to respond to rechallenge [39]. 
 The levels of T-bet and Eomes protein expression, as well as Blimp-1 mRNA 
expression, were not reduced in the absence of IL-2 signals.  Although we do not find an 
obligate role for IL-2 in inducing expression of any of these transcription factors during 
the in vivo response to viral infection, we do not rule out a role for IL-2 in controlling, 
directly or indirectly, their transcriptional activity. Although expression of the 
transcription factors T-bet, Eomes, and Blimp-1 are associated with effector CTL 
differentiation, less is known about how these transcription factors function and are 
regulated. For example, there may be activating and/or repressive binding partners 
and/or modifications affecting their activity. Thus, although our data shows that IL-2 is 
not obligatory for induction of expression of these factors, there are several ways in 
which IL-2 signals could result in alterations to transcriptional activity and, ultimately, 
the ability of a responding CD8+ T cell to undergo effector differentiation. Furthermore, 
even modest differences (<2-fold) in expression and/or activity of some of these 
transcription factors may have a profound impact on T cell differentiation and function. 
Future studies will be needed to precisely elucidate the combined role of these 
transcription factors and others (such as the Blimp-1 repressor Bcl-6[43, 44]) in the 
differentiation of CD8+ primary and secondary effector and effector memory T cells, 
along with the impact of inflammatory mediators and cytokines such as IL-2 on their 
activity. 
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 IL-2 is used as an immunotherapy in situations where the inflammatory burst is 
comparatively minimal, such as for antitumor immune responses [45]. IL-2 also appears 
to play a significant role in maintaining effector/memory responses during chronic 
infections [46], indicating that the long-term ability to respond to antigen may require 
IL-2. It is in this way, perhaps, that in vivo responses reflect the need for IL-2 in 
promoting the establishment and maintenance of T cell lines in vitro. We anticipate that 
a more detailed understanding of the role of IL-2 in the differentiation and function of 
antigen-activated T cells will greatly enhance our understanding of memory T cell 
biology. In particular, defining its role will aid in a variety of therapeutic strategies aimed 
at manipulating the T cell response. These include vaccination, immunotherapeutic or 
immunomodulatory strategies aimed at boosting the immune response, tumor 
eradication by immune cells, and strategies for which immunosuppression is desirable, 
such as for prevention of autoimmune responses or transplant rejection. 
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Introduction 
 Although IL-2 plays an important role in CD8+ secondary effector T cell 
differentiation following secondary challenge, we remained puzzled by our observation 
that IL-2 played a much more modest role in driving robust expansion during the 
primary response. One likely explanation is that during in vivo infection, other growth 
and inflammatory factors compensate for the absence of IL-2.  
 We hypothesized that related cytokines may compensate for the lack of IL-2 signals 
during acute infection. IL-15 was an obvious initial candidate. IL-2 and IL-15 belong to a 
family of cytokines utilizing the common gamma chain (γc) as a component of their 
receptors. Among this family, IL-2 and IL-15 are particularly related due to sharing the β 
(CD122) and γc (CD132) chains of their heterotrimeric receptor. Therefore, IL-2 and IL-
15 promote apparently distinct biological outcomes while utilizing similar JAK/STAT 
and protein tyrosine kinase (PTK) pathways [1, 2]. Because signals through both the IL- 
2R and the IL-15R are delivered by the β and γc chains, one possibility is that the 
biological effects of IL-2 and IL-15 signals in driving effector and memory CTL 
differentiation overlap.  
 However, IL-2 and IL-15 signals differ in magnitude, timing and context. While IL-
2 binds its receptor as a soluble molecule, IL-15 is presented in trans by surface-bound 
IL-15Rα [3, 4], restricting the most potent IL-15 signals to periods of cell-cell contact, 
such as during the interaction of a T cell with an antigen presenting cell (APC). In 
support of this idea, dendritic cells are a key source of IL-15 for memory T cell 
homeostasis and survival [5]. Furthermore, expression of the high-affinity IL-2R is 
largely restricted to the first few days of the response, whereas IL-15 signals are 
presumably available to T cells during the initiation of the T cell response as well as 
during memory maintenance. It is possible, therefore, that these differences can be 
invoked to explain the distinct biological impacts of IL-2 and IL-15 on the T cell 
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response. In this scenario, IL-15, rather than sharing a role with IL-2 during the primary 
response, could have opposing functions, such as have been suggested in the respective 
roles of IL-2 and IL-15 in driving the differentiation of effector and memory T cells [6, 7]. 
 Because IL-15 is highly related to IL-2 and shares a similar signaling apparatus, we 
hypothesized that IL-15 signals during the primary response could cooperate with IL-2 
and compensate for the lack of IL-2 signals in the differentiation of CD8+ effector and 
memory T cells. 
Materials and methods 
Mice and infections 
 6 to 8 week old C57BL/6 (B6) mice were purchased from Jackson Laboratories 
(Bar Harbor, ME). C57BL/6NTac-IL15tm1Imx (IL-15-deficient) were purchased from 
Taconic Farms (Germantown, NY). WT and IL-2Rα-deficient P14 TCR transgenic mouse 
colonies were maintained at the University of Utah. All animal experiments were 
conducted with the approval of the IACUC committee at the University of Utah. LCMV 
Armstrong 53b was grown in BHK cells and titered in Vero cells [8]. Mice were infected 
intraperitoneally (i.p.) with 2 x 105 plaque-forming units (PFU). Recombinant Listeria 
monocytogenes expressing the LCMV GP33-41 peptide (Lm-gp33, generated using 
described methods) was propagated in BHI broth and agar plates as previously described 
[9-11]. Prior to infection, the bacteria were grown to log phase and concentration 
determined by measuring the O.D. at 600 nm (O.D. of 1 = 1 x 109 CFU/ml). For 
secondary challenges, mice were injected intravenously (i.v.) with 2 x 105 colony forming 
units (CFU).  
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Cell suspensions and adoptive transfers  
 Splenocytes and lymph node cells were harvested at the indicated time points and 
re-suspended in RPMI 1640 supplemented with 10% FBS and antibiotics. Liver and lung 
lymphocytes were harvested by collagenase digestion as previously described [12]. 
Untouched CD8+ P14 T cells were isolated from the spleens and lymph nodes of WT or 
IL-2Rα-deficient P14 bone marrow chimeras by incubation with a biotinylated antibody 
cocktail followed by anti-biotin magnetic beads and depletion on a magnetic column, per 
manufacturer’s recommendations (Miltenyi). In addition, we added biotinylated CD44 
antibody (eBiosciences, San Diego, CA) to eliminate CD44hi “memory phenotype” P14. 
TCR transgenic T cell purity was assessed by staining with CD44, Vα2 and Vβ8.1 
antibodies, followed by flow cytometric analysis. WT (Thy1.1+) and IL-2Rα-deficient 
(Thy1.1+Thy1.2+) P14 were mixed 1:1 and co-injected i.v. into naïve B6 (Thy1.2+) mice at 
the indicated doses one day prior to infection. 
Peptide restimulation and intracellular cytokine staining 
 Splenocytes were resuspended in RPMI 1640 containing 10% fetal bovine serum 
and supplemented with antibiotics and L-glutamine. Mice were re-stimulated with 0.1 
µM H-2Db-restricted peptide (gp33-41) in the presence of Brefeldin A (1 µg/ml GolgiPlug). 
Cells were stained with cell surface antibodies, permeabilized and stained with cytokine 
antibodies (specific to IFNγ, TNFα and IL-2) using a kit per manufacturer’s instructions 
(BDBiosciences, Mountain View, CA). 
Antibodies and flow cytometry 
 Fluorescent dye-conjugated antibodies were purchased from eBioscience (San 
Diego, CA), BioLegend (San Diego, CA) or BDBiosciences (Mountain View, CA) with the 
following specificities: CD8, Thy1.1, Thy1.2, CD45.1, Va2, Vb8.1, CD44, IL-7Rα, KLRG1, 
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CD27, CD62L, CXCR3, CD43, CD122, TNFα, IL-2 and IFNγ. Cell surface antibody 
staining was done in PBS containing 2% FBS, and intracellular cytokine staining was 
performed as described above. For T-bet and Granzyme B staining, cells were 
permeabilized using the same buffers as for intracellular cytokine staining 
(BDBiosciences, Mountain View, CA). For Eomes, cells were permeabilized and stained 
using the same buffers as those used for the anti-FoxP3 antibody per the manufacturer’s 
instructions (eBioscience, San Diego, CA).  Multi-parameter (6-7 color) analysis of 
antibody-stained cells was performed on a FACSCanto II flow cytometer (BDBiosciences, 
Mountain View, CA) and results analyzed using FlowJo software (TreeStar). Cell sorting 
was with on a FACSVantage (BDBiosciences, Mountain View, CA) at the University of 
Utah FACS core facility. 
Results 
IL-2 and IL-15 jointly promote the emergence and 
survival of effector CTL 
 In order to probe a joint role for IL-2 and IL-15 signals to CD8+ T cells, we 
adoptively co-transferred WT and IL-2Rα-deficient P14 cells into either WT or IL-15-
deficient hosts. Because mouse CD8+ T cells are not an in vivo source of IL-15 in mice, we 
were able to assess the response of P14 T cells in the absence of either IL-2 or IL-15 
signals, or both. At the peak of the primary response (day 8 postinfection), the absence of 
either IL-2 or IL-15 alone resulted in a similar decrease (~2-3-fold) in the number of 
end-stage effector cells (KLRG1hiIL-7Rlo). The combined absence of both IL-2 and IL-15 
signals to CD8+ T cells resulted in a further significant decrease in the number of effector 
CTL cells at the peak of the response, as compared to the absence of IL-2 or IL-15 signals 
alone (Fig. 3.1A, B). By day 42 postinfection, we observed a 10-20-fold decrease in the 
number of terminal effector phenotype cells in the absence of IL-2 signals, as compared  
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Figure 3.1 IL-2 and IL-15 jointly promote the persistence of terminal effector phenotype, 
but not long lived effector memory CD8+ T cells.  We transferred 5x103 WT and IL-2Rα-
/- P14 into B6 and IL-15-/- hosts and infected with LCMV.  A) The bar graphs display the 
number of terminal effector phenotype (KLRG1-hi, IL-7Ra-lo) WT and IL-2Rα-/- P14 
responders in B6 or IL-15-/- hosts at days 8 or 42 postinfection.  Error bars indicate 
SEM (n=3). The decrease of P14 cells in the absence of both cytokines, as compared to 
each cytokine alone, is statistically significant at both time points (p<0.05).  B) 
Representative flow plots indicate the relative frequencies of effector (KLRG1-hi, IL-7Ra-
lo) and memory (KLRG1-lo, IL-7Ra-hi) phenotype cells among WT and IL-2Rα-/- P14 
responders in B6 or IL-15-/- hosts at the indicated time points postinfection.  C) The bar 
graph indicates the relative frequency of CD62L-hi cells among WT and IL-2Rα-/- 
memory phenotype P14 responders (KLRG1-lo, IL-7Ra-hi) in B6 or IL-15-/- hosts at the 
indicated time points postinfection.  Error bars represent the SEM (n=3).  Results are 
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to WT responses. The absence of IL-15 resulted in a similar decrease in the number of 
terminal effector phenotype cells at this time point. In the joint absence of IL-2 and IL-15 
signals, this population was essentially undetectable, indicating a joint role for IL-2 and 
IL-15 in the differentiation and/or persistence of terminal effector phenotype CD8+ T 
cells (Fig. 3.1A, B).  These findings were independent of IL-15R expression, as WT and 
IL-2Rα-deficient P14 cells expressed similar levels of IL-15Rβ (CD122) regardless of the 
host (Fig. 3.2).  Furthermore, differences could not be attributed to a lack of cell division, 
as similar frequencies of P14 cells expressed the cell cycle marker Ki-67 regardless of the 
presence of IL-15 (data not shown). 
 We further sought to determine whether IL-15 played a joint role with IL-2 in 
promoting the differentiation of effector memory CD8+ T cells, as measured by CD62L 
expression. In this case, however, IL-15 appeared to play no role. While the absence of 
IL- 2 signals resulted in a more rapid skewing of the IL-7Rαhi memory precursor 
populations to a CD62Lhi central memory-like phenotype, the absence of IL-15 signals 
had no such effect, either alone or in combination with the absence of IL-2 signals (Fig. 
3.1C). Because IL- 15 is required for the homeostatic division and maintenance of CD8+ 
memory T cells [13], we did not assess later memory time points, focusing instead on the 
role of IL-15 in the initial establishment of memory. These findings indicated that IL-15 
might play a joint role with IL-2 in promoting the differentiation and/or survival of 
effector CD8+ T cells but suggested distinct roles for these two cytokines in the 
differentiation of CD8+ memory T cell subsets. While IL-15 promotes the survival and 
turnover of CD8+ memory T cells over long periods of time, we saw little impact on CD8+ 
memory T cell numbers in the absence of IL-15 at the early memory time points assessed 
in this study, consistent with prior reports [14]. 







Figure 3.2 IL-2Rα-deficient and WT CD8+ memory T cells express similar levels of 
CD122 in WT and IL-15-/- hosts. WT and IL-2Rα-/- P14 (5000 of each) were co-
transferred into B6 or IL-15-/- mice, followed by infection with LCMV one day later. 
Representative flow plots (n=3-4/time point in each group) indicate CD122 (IL-2Rβ) 
expression by P14 CTL of the indicated genetic background in the indicated hosts at day 





































Supplemental Figure 6. IL-2Rα-deficient and WT CD8+ memory T cells 
express similar levels of CD122 in WT and IL-15-deficient hosts. WT and 
IL-2Rα-deficient P14 (5 x 103 of each) were co-transferred into B6 or IL-15-
deficient mice, followed by infection with LCMV one day later.  Representative 
flow plots (n=3-4/time point in each group) indicate CD122 expression by P14 
CTL of the indicated genetic background in the indicated hosts at day 8, 15 or 
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Supplemental Figure 6. IL-2Rα-deficient and WT CD8+ memory T cells 
express similar levels of CD122 in WT and IL-15-deficient hosts. WT and 
IL-2Rα-deficient P14 (5 x 103 of each) were co-transferred into B6 or IL-15-
deficient mice, followed by infection with LCMV one day later.  Representative 
flow plots (n=3-4/time point in each group) indicate CD122 expression by P14 
CTL of the indicated genetic background in the indicated hosts at day 8, 15 or 
42 post-infection.  Results are representative of three separate time courses.  
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Disparate roles for IL-2 and IL-15 in the differentiation and 
survival of KLRG1hiIL- 7Rαlo effector CTL 
 We considered two possible roles for IL-15 in promoting effector CTL populations. 
First, IL-15 signals during the priming and expansion phase might be important for their 
differentiation, similar to the role of IL-2. Our initial transfers of P14 cells into IL-15-
deficient animals seemed to imply that this could be the case at least in part, as fewer 
terminal effector phenotype CTL were present at the peak of the primary response in the 
absence of IL-15 or IL-2 signals alone, and further decreased in their joint absence. On 
the other hand, IL-15 has been shown to play a key role in the survival of KLRG1hiIL-7Rlo 
terminal effector phenotype CTL during the contraction phase [15-17], and we 
considered as an alternative that IL-15 was required only for the survival of these cells, 
not their differentiation. 
 In order to distinguish a potential differentiation role for IL-15 during the primary 
response from its known survival role thereafter, we limited, through adoptive transfer, 
the availability of IL-15 signals to WT or IL-2Rα-deficient P14 responders to the primary 
phase (days 0-8) or the contraction phase (days 8-42) of the T cell response. We co-
transferred WT and IL-2Rα-deficient P14 in into B6 mice and infected with LCMV. At 
day 8 postinfection, WT and IL-2Rα-deficient P14 CTL were harvested from the spleen 
and transferred into infection-matched B6 or IL-15-deficient secondary hosts. We 
subsequently analyzed the persistence of WT or IL-2Rα-deficient terminal effector 
phenotype cells that lacked IL-15 signals during the primary response only, during the 
contraction phase only, or both. As before, we found that the absence of IL-15 during 
both the primary response and the contraction phase severely curtailed the persistence 
of KLRG1hiIL-7Rαlo effector cells and that the effect was exacerbated in the additional 
absence of IL-2 (Fig. 3.3). Similar results were observed when IL-15 signals were absent  
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Figure 3.3 IL-15 is required for the survival but not differentiation of terminal effector 
phenotype CTL.  We transferred 5x103 WT and IL-2Rα-/- P14 into B6 and IL-15-/- hosts 
and infected with LCMV.  At day 8 postinfection, we isolated CD8+ T cells from their 
spleens using magnetic beads and transferred them to infection-matched secondary B6 
or IL-15-/- hosts.  Representative flow plots indicate the relative frequencies of effector 
(KLRG1-hi, IL-7Rα-lo) and memory (KLRG1-lo, IL-7Rα-hi) phenotype cells among WT 
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during the contraction phase only (Fig. 3.3) In contrast, the absence of IL-15 during the 
primary response alone resulted in levels of effector CTL levels similar to those seen 
following transfer of WT and IL-2Rα-deficient P14 into WT B6 hosts (Fig. 3.3). These 
findings conclusively demonstrate that in contrast to IL-2 the primary role for IL-15 in 
this setting is the survival of KLRG1hi terminal effector phenotype CTL, not their 
differentiation. 
IL-15 is not required for secondary CD8+ T cell expansion 
and effector differentiation 
 We next assessed whether IL-15 shared an overlapping role with IL-2 in the 
differentiation of CD8+ memory T cells capable of secondary responses. We co-
transferred 500 WT and IL-2Rα-deficient P14 into B6 or IL-15-deficient mice and 
infected with LCMV as previously. At 42 days postinfection, mice were rechallenged with 
Lm-gp33. WT P14 memory cells expanded robustly by day 5 postrechallenge regardless 
of the presence or absence of IL-15 signals (Fig. 3.4A). They also differentiated into 
secondary effector CTL as determined by expression of IL-7Rα and KLRG1 (Fig. 3.4B) 
and their cytokine production profile (Fig. 3.4C). As observed previously, IL-2Rα-
deficient memory cells responded poorly to secondary challenge and failed to acquire 
phenotypic or functional (cytokine-producing) characteristics indicative of secondary 
effector differentiation. However, this phenotype was not exacerbated in the absence of 
IL-15, again indicating that the functional role of IL-2 and IL-15 in CTL memory 
differentiation and survival were non-overlapping (Fig. 3.4A, B, C). 
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Figure 3.4 IL-15 is not required for the generation of secondary effector CTL.  We 
transferred 500 WT and IL-2Rα-/- P14 into B6 and IL-15-/- hosts and infected with 
LCMV. At day 42 postinfection, we rechallenged mice with Lm-gp33 and assessed recall 
responses in the spleen 5 days later.  A) The bar graph indicates the fold expansion 5 
days after rechallenge of WT and IL-2Rα-/- P14 responders in B6 or IL-15-/- hosts.  
Error bars indicate SEM (n=3/group).  B) The pie charts indicate the average frequency 
of WT or IL-2Rα-/- P14 secondary responders in WT or IL-15-/- hosts that make IFN-
gamma after 4-hour restimulation and that also produce TNFα and/or IL-2 (n=3).  C) 
Representative plots indicate the relative frequency of terminal effector phenotype 
secondary responders (KLRG1-hi, IL-7Rα-lo) among WT and IL-2Rα-/- P14 cells in WT 
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Discussion 
In the absence of IL-2 signals, effector CTL undergo massive primary expansion. 
It is possible that the milieu of growth and inflammatory factors available during the 
infectious burst can compensate for the lack of IL-2 signals. This hypothesis is supported  
by the fact that IL-2 is one member of a family of cytokines linked by their receptor 
usage. Because the signaling apparatus used by IL-2 and IL-15 is largely shared, it is 
presently unclear what the differences are in the signals that account for their distinct 
biological effects. While we find a role for IL-15 in the survival of CD8+ effector T cells 
after antigen clearance, it does not play a role in the differentiation of this population 
during primary activation, nor is it required for the differentiation of functionally 
competent CD8+ memory T cells. Instead, our findings suggest that IL-15 plays a 
fundamentally distinct role from that of IL- 2, promoting not the differentiation, but 
survival of CD8+ memory T cells. 
 We find little role for IL-15 signals during the primary response, either alone or in 
combination with IL-2, in promoting effector or effector memory differentiation or 
programming the recall capacity of CD8+ central memory T cells.  Instead, the dominant 
role of IL-15 was to promote the survival of effector and memory populations after 
pathogen clearance.  While excess IL-15 signals may serve as an adjuvant or have 
immunotherapeutic benefit for CD8+ T cell responses, our findings suggest that in 
settings of acute infection, physiological IL-15 signals to T cells during the primary 
response do not play a significant role in CD8+ effector and memory T cell 
differentiation, particularly as compared to IL-2. 
 It is not clear, however, whether the programming of functional memory cells by 
IL-2 represents a unique signal from IL-2 that other γc-family member cytokines are 
unable to deliver, or if it represents a common signal, that any member of the family 
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could redundantly deliver during T cell activation and differentiation, were it present in 
sufficient amounts and its receptor expressed.  
 Our results suggest that IL-15 signals do not overlap with IL-2 signals, but this may 
reflect differences in receptor expression and cytokine availability resulting in different 
contexts of cytokine stimulation.  Because IL-15 is expressed in trans [4], T cells must be 
in close proximity to potential IL-15 producers, whereas, IL-2 is secreted into the 
environment.  It is unclear the extent to which IL-15 signals are available to 
differentiating CTLs during the primary response, but IL-15 presented by dendritic cells 
has been shown to induce homeostatic proliferation of memory T cells [5].  It is possible 
that the levels of IL-15 available to CD8+ T cells differ depending on the nature of the 
pathogenic stimulus, and our results do not rule out a potential role for IL-15 during 
primary CD8+ T cell differentiation if present at high enough concentrations in other 
infectious model systems. 
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DIFFERENT REQUIREMENTS FOR STAT5 
IN PRIMARY AND SECONDARY 






Environmental signals, including cytokine signals, received by CD8+ T cells 
during the primary immune response have an essential role in effector and memory 
CD8+ T cell differentiation [1]. The common gamma chain (γc) family cytokine IL-2 has 
been shown to drive CD8+ T cell effector and memory differentiation [2-5].  We and 
others have shown a role for IL-2 during the primary immune response in driving 
differentiation of effector CTL [2-4], as well programming of memory CD8+ T cells 
capable of robust recall responses [3, 5].  
How CD8+ T cells integrate signals by cytokines to determine fate decisions are 
not fully understood.  Specifically, how do cytokines, such as IL-2, induce signaling 
pathways that result in long-lived memory CD8+ cells capable of protective recall 
responses?  Several transcription factors, including T-bet [6-11], Eomes [6, 8, 12, 13], 
Blimp-1 [14-18], and Bcl-6 [14, 19, 20], have been shown to have crucial roles in CD8+ T 
cell effector differentiation and effector versus memory fate decisions.  In the case of T-
bet [6, 8-11] and Blimp-1 [14, 16-18], increased activity promotes a more differentiated 
terminal effector state in CD8+ T cells.  On the other hand, Eomes [6, 8, 12, 13] and Bcl-6 
[14, 19, 20] are associated with establishment of long-lived memory CD8+ T cell 
populations.  In the case of effector CD4+ T cell differentiation, connections between 
cytokines and transcriptional programs is relatively well described and in several 
lineages involves STAT  proteins [21].  In contrast, the molecular connection between 
environmental signals, such as cytokines, received by CD8+ T cells during an immune 
response and the resulting transcriptional outcome driving differentiation towards 
terminal effector versus memory CD8+ T cell fate is less clear. 
We have shown a crucial role for the cytokine IL-2 in the differentiation of 
effector and memory CD8+ T cells [3, 5].  Signals from IL-2 during the primary response 
to infection are critical in promoting the differentiation of effector and effector memory 
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CTL [3].  Moreover, IL-2 signals received by CTL during the primary response program 
memory CD8+ T cells capable of robust secondary responses [3, 5] and secondary 
effector differentiation [3].  We sought to determine the signaling pathways induced by 
IL-2 during a primary immune response that are involved in CD8+ T cell fate decisions 
and memory CD8+ T cell programming.  The JAK3/STAT5, PI3K/Akt, and MAPK 
signaling pahways are potently activated by IL-2 [22].  Of these pathways, PI3K/Akt and 
MAPK are activated by a variety of other cytokine receptors, TCR ligation, and 
costimulatory signals [23-26] during T cell activation.  Other γc cytokines in addition to 
IL-2, such as IL-7 and IL-15, also activate JAK3/STAT5, but the timing and context of 
this signaling differ due to cytokine availability and differential regulation of the specific 
receptor subunits [27].   IL-2 potently activates STAT5 during the differentiation of 
effector CTL.  While IL-15 and IL-7 are present during the effector CTL response, their 
primary role appears to be in the maintenance of memory T cells after antigen clearance 
[27, 28].  Moreover, IL-15 and IL-7 signals are not required for the programming of 
memory CD8+ T cells [3, 29, 30] as is the case with IL-2 [3, 5].   Therefore, IL-2 is the 
most likely catalyst for robust STAT5 activation during primary CTL responses, and we 
hypothesized that IL-2-mediated activation of STAT5 was a key step in the 
differentiation of highly functional CD8+ memory T cells.   
Two isoforms of STAT5 exist, STAT5a and STAT5b, which have redundant 
functions in T cell homeostasis [31, 32].  Mice with deletion of both stat5a/b fail to 
develop T cells [33, 34], demonstrating that STAT5 is essential for T cell development.  
Recent reports examined the role of STAT5 in the survival of effector and memory CD8+ 
T cells after pathogen clearance [35, 36].  In the absence of STAT5, effector CD8+ T cells 
show reduced accumulation at the peak of the primary response to infection, possibly 
due to their inability to induce Bcl-2 via STAT5 in response to IL-7 and IL-15 [36].  
Forcing expression of a constitutively active form of STAT5 increased the numbers of 
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effector CTL at the peak of the primary response to LCMV, and augmented survival of all 
CD8+ T cell subsets through contraction and memory [35].  This was possibly due to 
increased augmentation of as well as access to PI3K/Akt signaling in the presence of 
STAT5 signaling.  These studies support STAT5 signaling in effector and memory CD8+ T 
cell survival, mainly in the context of IL-15 and IL-7 signaling.  However, the function of 
STAT5 signals during the primary response to infection, as driven by IL-2, in CTL 
differentiation, fate decisions, and memory CD8+ T cell programming has not been 
examined. 
To determine the contribution of STAT5 to CD8+ effector and memory T cell 
differentiation, we employed a model in which stat5a/stat5b are inducibly deleted upon 
CTL activation.  We find that STAT5 is broadly important for all effector CD8+ T cell 
subsets during the primary response to acute infection, but is selectively important for 
the survival of terminal effector phenotype CTL and tissue residing memory CD8+ T cells 
during contraction.  After contraction, memory CD8+ T cell populations formed in the 
absence of STAT5 are readily detectable at 6 weeks postinfection.  While STAT5 was 
required for robust expansion and survival of primary effector CTL, STAT5-deficient 
memory CD8+ T cells mounted robust recall responses comparable to wild-type levels 
and underwent effective secondary effector CTL differentiation.  Our findings highlight a 
differential requirement for survival signals mediated by STAT5 during primary and 
secondary CD8+ T cell responses.  Moreover, our data suggest that IL-2 driven 
differentiation and programming of memory CD8+ T cells with robust recall potential is 




Materials and methods 
 
Mice and infections 
4 to 6 week old B6.PL-Thy1a/CyJ (B6.PL, Thy1.1+) and C57BL/6 (B6, Thy1.2+) 
mice were purchased from Jackson Laboratories (Bar Harbor, ME).  GzB-Cre [37], 
Rosa26-fl/stop/fl-YFP (RosaYFP) [38] (Jackson Laboratories), and stat5fl/fl [39] mouse 
colonies were maintained at the University of Utah (Salt Lake City, UT).   All 
experiments were performed with the approval of the IACUC committee at the 
University of Utah.  Lymphocytic choriomeningitis virus (LCMV) strains Armstrong 53b 
and clone 13 were grown in BHK cells and titered in Vero cells as described [40].  
Primary infection was at a dose of 2 x 105 PFU i.p.  For secondary challenges, mice were 
given 2 x 106 PFU LCMV-Cl.13 i.v. or 2 x 105 PFU LCMV-Arm i.p.  Recombinant Listeria 
monocytogenes expressing the LCMV GP33-41 peptide (Lm-gp33, generated using 
described methods) was propagated in BHI broth and agar plates as previously described 
[41-43].  Prior to infection, the bacteria were grown to log phase and concentration 
determined by measuring the O.D. at 600 nm (O.D. of 1 = 1 x 109 CFU/ml). For 
secondary challenges, mice were injected intravenously (i.v.) with 10,000 colony forming 
units (CFU). 
Irradiation chimeras 
Host B6.PL (Thy1.1+) mice were given a dose of 900 rads using the analytical x-
ray irradiator in the mouse vivarium at the University of Utah.  The next day, mice 
recieved 5 x 106 bone marrow (BM) cells harvested from the femurs and tibias of donor 
mice as indicated.  BM cells were prepared by RBC lysis and depletion of CD3+ cells 
using biotinylated anti-CD3 antibody (eBioscience, San Diego, CA), anti-biotin magnetic 
beads (Miltenyi Biotec, Auburn, CA), and passage through magnetic column following 
manufacturer’s guidelines (Miltenyi Biotec).  WT B6.PL (Thy1.1+) BM was mixed 1:1 with 
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either GzB-Cre-RosaYFP-stat5wt/wt(Thy1.2+) or GzB-Cre-RosaYFP-stat5fl/fl(Thy1.2+) BM 
and injected i.v. into the irradiated hosts.  After 8-10 weeks, reconstitution within the 
CD8+ T cell population was determined using antibodies to the congenic markers Thy1.1 
and Thy1.2. 
Cell suspensions and cell sorting 
Splenocytes and lymph node cells were harvested at indicated time points 
postinfection and placed in single cell suspension in RPMI 1640 with 10% FBS, L-
glutamine, and Pen/Strep prior to further analysis.   Liver lymphocytes were harvested 
and subjected to collagenase digestion as previously described [44].  Cell sorting of 
CD8+YFP+ cells was performed using a FACS Aria II cell sorter (BD Biosciences) at the 
University of Utah FACS Core Facility, followed by immediate adoptive transfer by i.v. 
injection into the indicated secondary hosts. 
Flow cytometry and analysis 
Antibodies (Abs) conjugated to fluorescent dyes were purchased from 
eBioscience (San Diego, CA), Biolegend (San Diego, CA), or BD Biosciences (Mountain 
View, CA).  Abs were specific for the following antigens: CD8, Thy1.1, Thy1.2, KLRG1, 
IL7Rα, CD62L, T-bet, Eomesodermin (Eomes), Bcl6, GranzymeB, STAT5-pY694.  For 
cell surface staining, single cell suspensions were incubated with Abs in FACS Buffer 
(PBS with 2% FBS and 0.02% sodium azide).  For intracellular staining of T-bet and 
GranzymeB, cells were permeabilized and stained using the BD Cytofix/CytopermTM kit 
and manufacturer’s instructions (BD Biosciences).  For intracellular staining of Eomes, 
cells were pre-fixed in 0.5% PFA to preserve the YFP signal, washed twice, then fixed 
using FoxP3 Fix/Perm Buffer kit and manufacturer’s instructions (eBioscience).  To 
detect STAT5-pY694, the BD PhosflowTM kit and manufacturer’s protocol were followed 
(BD Biosciences). H-2Db/GP33-41 and H-2Db/NP396-404 were prepared as previously 
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described [45, 46]. Multiparameter analysis of stained cells was performed using a 
FACSCanto II flow cytometer (BD Biosciences) and results were analyzed using FlowJo 
software (TreeStar, Ashland, OR).   
Intracellular cytokine staining 
Single cell suspensions in RPMI 1640 containing 10% FBS, L-glutamine, and 
penicillin/streptomycin were incubated with 0.1 uM GP33-41 or NP396-404 peptides in the 
presence of GolgiPlug (BD Biosciences) for 5 hours per the manufacturer’s instructions.  
Cells were stained with cell surface Abs, fixed and permeablized using a kit (BD 
Biosciences) and stained with fluorescently labeled anti-cytokine Abs specific to IFN-γ, 
TNF-α, and IL-2 (eBioscience). 
CTL assays 
We used a CTL assay as previously described [6].  EL-4 targets cells were 
incubated with 0.1uM GP33-41 peptide for 2 hrs at 37° C.  Cells were washed and then 
incubated with sorted STAT5 WT or STAT5 CKO P14 CTLs for 2 hrs at CTL:target ratios 
ranging from 3:1 to 0.1:1.  The percentage of Annexin V+ target cells was determined by 
FACS using Annexin V-APC apoptosis detection kit (eBioscience).  Specific lysis was 
determined by comparison of killing of target cells without peptide loading.   
Real-time PCR 
RNA was extracted from sorted YFP+CD8+ T cells using Trizol (Invitrogen, 
Carlsbad, CA).  cDNA was prepared from the RNA and qRT-PCR was performed using 
SuperscriptTM III Platinum® Two-Step qRT-PCR Kit with SYBR® Green (Invitrogen, 
Carlsbad, CA) following the manufacturer’s guidelines.   Primer sets used are as follows: 
Eomes: f-CCGCCCACTACAATGTTTTC, r-GAAATCTCCTGCCTCATCCA; T-bet: f-
CCCACAAGCCATTACAGGAT, r-CCCTTGTTGTTGGTGAGCTT; Blimp-1: f- 
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CGGGATGAACATCTACTTCTACACT, r-TTTCTTTCACGCTGTACTCTCTCTT; Bcl-6: f- 
CCGGCTCAATAATCTCGTGAA, r-GGTGCATGTAGAGTGGTGAGTGA; FasL: f- 
CATCACAACCACTCCCACTG, r-TACTGGGGTTGGCTATTTGC; Prf1: f- 
GCAGCTGAGAAGACCTATCAGGAC, r-TCTGAGCGCCTTTTTGAAGTC; Bcl-2: f- 
GTGGTGGAGGAACTCTTCAGGGATG, r-GGTCTTCAGAGACAGCCAGGAGAAATC; Bim: 
f-CGGATCGGAGACGAGTTCA, r-TTCAGCCTCGCGGTAATCA; mcl-1: f-
AGAGCGCTGGAGACCCTG, r-CTATCTTATTAGATATGCCAGACC; Bcl-XL: f- 
GTAGTGAATGAACTCTTTCGGGATGG, r-ACCAGCCACAGTCATGCCCGTCAGG.  Real-
time PCR and analysis was performed using a Roche LightCycler® 480 (Roche, 
Indianapolis, IN).   
Results 
 
STAT5 is required for accumulation of effector CTL 
during acute infection 
In order to study the role of STAT5 signals in CD8+ T cell effector and memory 
differentiation, we created a mouse bone marrow chimera model system in which stat5a 
and stat5b are deleted in activated CD8+ T cells, and the resulting STAT5-deficient CD8+ 
T cells are traceable by permanent expression of YFP (Fig. 4.1A).  Bone marrow was 
harvested from mice with the following genetic components: Cre recombinase driven by 
the GranzymeB promoter [37] (GzB-Cre), RosaYFP reporter construct [38], and the 
stat5a/b genes flanked by loxP sites [39] (stat5fl/fl), which we will subsequently refer to 
as “STAT5 conditional knockout (CKO)” bone marrow.  The donor bone marrow was 
mixed 1:1 with wild-type B6.PL bone marrow (“WT”) and transplanted into irradiated 
B6.PL hosts.  This set of chimeras will subsequently be referred to as STAT5 CKO 
chimeras.  A second set of bone marrow chimeras was made in an identical fashion, 












Figure 4.1 Validation of STAT5 CKO model system.  A, Schematic showing creation of  
STAT5 WT and STAT5 CKO bone marrow chimeras for model system to study CD8+ T 
cell responses in the absence of STAT5.  B, Representative flow plots showing 
CD8+YFP+ populations in the STAT5 (Thy1.2+) component of both STAT5 WT and 
STAT5 CKO chimeras at day 8 postinfection with LCMV.  C, Splenocytes from STAT5 
WT or STAT5 CKO Chimeras harvested on day 8 or day 40 postinfection were cultured 
with 500 U/mL mIL-2 then stained for phospho-STAT5.  Representative histogram 
shows P-STAT5 levels in unstimulated controls (gray shaded), CD8+YFP+ T cells from 
STAT5 WT chimeras (black line), and CD8+YFP+ T cells from STAT5 CKO chimeras 
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(stat5wt/wt) and will be referred to as STAT5 WT chimeras (Fig 4.1A).  We distinguished 
between STAT5 (Thy1.2+) and B6.PL (Thy1.1+) donor-derived T cells over the course of 
infection based on differential expression of congenic Thy1 alleles.  In this model system, 
activation of Cre activity upon CTL activation, driven by Granzyme B induction, results 
in the deletion of LoxP-flanked stat5a/b as well as a LoxP-flanked stop codon preceding 
YFP under the control of the Rosa26 promoter.  Because Granzyme B expression is one 
of the earliest events following CTL activation, permanent YFP expression serves as an 
effective surrogate marker for Cre-mediated gene deletion during CTL differentiation 
and expansion. 
Following infection with LCMV-Armstrong, CD8+ T cell expansion was evident in 
both STAT5 WT and STAT5 CKO chimeras, and both groups of chimeras cleared the 
infection as expected (data not shown).  A clearly distinguishable CD8+YFP+ population 
was seen in both STAT5 WT and STAT5 CKO chimeras on day 8 postinfection (Fig. 4.1B).  
Importantly, we were able to confirm that STAT5 was absent from the CD8+YFP+ 
population within the STAT5 CKO chimeras at effector and memory time points (Fig. 
4.1C). 
Following LCMV infection, we observed a defect in the overall expansion of 
CD8+YFP+ effector CTLs in the spleen in the absence of STAT5.  While STAT5 WT 
chimeras displayed similar expansion of CD8+ T cells derived from either donor, STAT5 
CKO chimeras displayed deficient expansion by CD8+ T cells derived from the STAT5 
CKO donor (Fig. 4.2A).  By day 8 postinfection, the CD8+ T cell population in the spleens 
of STAT5 CKO chimeras was almost entirely derived from the WT donor (Fig. 4.2B).  
This shows a decreased accumulation of STAT5 CKO CD8+ T cells at day 8 postinfection 
compared to WT.   
We examined STAT5 WT and STAT5 CKO CD8+ T cells for differences in anti-










Figure 4.2 STAT5 is required for full primary expansion of CD8+ T cells.  A, The ratio of 
“WT” to “STAT5” components in the CD8+ T cell compartment are shown for both sets 
of chimeras prior to (day 0) and day 8 post LCMV infection.  B, Total numbers of CD8+ 
T cells from “WT” and “STAT5” components on day 8 post LCMV infection in STAT5 WT 
and CKO chimeras.  Error bars indicate the SEM (n=3-4 mice per time point).  Results 









































Table 4.1 Gene expression in CD8+YFP+ WT STAT5 compared to CD8+YFP+ STAT5 
CKO T cells day 8 postinfection with LCMV.  Fold differences are significant for p<0.05, 




Fold expression in WT STAT5 
compared to STAT5 CKO 
Tbet 1.57 (p=0.008) 
Blimp-1 1.82 (p=0.021) 
Perforin 1.55 (p=0.010) 
Bcl-6 0.23 (p=0.041) 
EOMES 1.42 (p=0.150) 
FasL 0.95 (p=0.859) 
Bcl2 0.71 (p=0.365) 
Bcl-XL 1.77 (p=0.046) 
Bim 1.17 (p=0.642) 





LCMV and found no significant differences in expression of the pro-survival genes Bcl-2 
and Mcl-1 and no difference in expression of the pro-apoptotic gene Bim (Table 4.1).   
STAT5 WT CD8+ T cells showed a modest increase in expression of Bcl-xL over STAT5 
CKO CD8+ T cells (Table 4.1). 
We next examined how STAT5-deficiency affected antigen-specific CD8+ T cells 
responding to acute infection by staining with MHC Class I tetramers for two 
immunodominant LCMV epitopes.  While the frequency of H-2Db/GP33-41 and H-
2Db/NP396-404 tetramer+ cells was similar in the STAT5 WT and STAT5 CKO CD8+ T cell 
populations (Fig. 4.3A), due to the overall loss in CD8+ T cells the total numbers of 
STAT5 CKO antigen specific CD8+ T cells was substantially lower than WT at the peak of 
the response in the spleen (Fig. 4.3B).  Because measuring total numbers does not take 
into account the change in frequency of donor CD8+ T cells seen between day 0 and day 
8 postinfection (Fig. 4.2A), we normalized the CTL response in each chimera to the 
predicted response based on the ratio of donor WT to donor STAT5 WT or STAT5 CKO 
CD8+ T cells prior to infection.  We found that the STAT5 CKO antigen specific CD8+ T 
cell response was approximately 4-fold lower than the wild-type response seen by STAT5 
WT CTLs (Fig. 4.3C).  Importantly, these differences were not due to inefficient deletion 
of STAT5 as antigen specific YFP+ STAT5 CKO CTLs displayed virtually no STAT5 
expression at day 8 postinfection (Fig. 4.3D).  We conclude that STAT5 is an important 
survival signal for CD8+ T cells undergoing expansion during primary immune challenge. 
STAT5 influences CTL function but does not drive 
CTL differentiation 
To explore whether STAT5 influenced effector CTL differentiation, we examined 
the localization, expression of effector molecules and function of effector CTLs in the 




Figure 4.3 Antigen specific STAT5 CKO primary responses are reduced in number 
compared to wildtype. A, Representative flow plots show the frequency of antigen 
specific (H2Db-GP33-41 tetramer+) YFP+ within the CD8+ population in the spleen on 
day 8 post LCMV infection. B, Total numbers of WT and STAT5 CKO CD8+ T cells on 
day 8 postinfection for two LCMV-specific epitopes.  C, Differences in absolute numbers 
seen on day 8 postinfection for antigen-specific CD8+ T cells were normalized to reflect 
changing ratios of WT  and STAT5 counterparts seen between day 0 and day 8 
postinfection (Fig 1D).  Graphs showing the % of normalized response are displayed for 
two antigen-specific CD8+ T cell populations in a representative experiment.  Error bars 
represent the SEM (n=3-4 per group). D, Confirmation of deletion of STAT5 within 
antigen specific YFP+CD8+ T cells from STAT5 CKO Chimeras.  Splenocytes from 
STAT5 WT and CKO Chimeras were harvest on day 8 post LCMV infection, surface 
stained for CD8 and tetramers, cultured with 500U/mL IL-2, then stained for P-STAT5.  
Representative histogram shows P-STAT5 levels in unstimulated controls (gray shaded) 
and tetramer+YFP+CD8+ T cells from either STAT5 WT (black line) or STAT5 CKO 













































































































Figure 4.4 Effector CTL function is modestly reduced in the absence of STAT5.  A, 
Representative flow plots show the frequency of antigen specific (H2Db-GP33 
tetramer+) YFP+ within the CD8+ population in the liver on day 8 postinfection with 
LCMV.  B, Cytokine expression was determined by ex vivo GP33-41 peptide restimulation 
of splenocytes on day 8 postinfection.  Representative flow plots display IFN-γ and TNF-
α production gated on CD8+YFP+ T cells from from STAT5 WT  or STAT5 CKO 
chimeras.  C, Intracellular expression of GranzymeB, T-bet, EOMES, and Bcl-6 on day 8 
postinfection in STAT5 WT (black line) and STAT5 CKO(gray line) GP33  tetramer+ 
CD8+ T cells.  Gray filled histograms display isotype control staining.  D, Target cells 
loaded with GP33-41 peptide were incubated with STAT5 WT or STAT5 CKO CTL FACS 
sorted from spleens at day 8 postinfection.  CTL induced lysis was measured by staining 
with Annexin V after 2 hrs.  % specific lysis was determined by comparison to Annexin 
V+ target cells that were not loaded with peptide.  E, Degranulation measured by CD107a 
staining of ex vivo GP33 peptide stimulated splenocytes on day 8 postinfection.  Error 
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at similar frequencies in the liver of LCMV infected mice on day 8 postinfection (Fig. 
4.4A), demonstrating that CTL form and traffic to peripheral sites of infection even in 
the absence of STAT5.  Additionally, STAT5 CKO CD8+ T cells produced IFN-γ and TNF-
α at similar frequencies and levels upon peptide restimulation of splenocytes (Fig 4.4B) 
and liver lymphocytes (data not shown). STAT5 CKO tetramer binding CD8+ T cells 
readily expressed similar levels of the cytolytic molecule GranzymeB (GzB) as STAT5 WT 
tetramer binding cells on day 8 postinfection (Fig. 4.4C).  In addition, STAT5 CKO CTL 
degranulated normally upon peptide restimlulation, as measured by the surface 
expression of CD107a following peptide restimulation (Fig. 4.4E).   
Modest differences in mRNA levels (Table 4.1) were seen for two transcription 
factors, T-bet and Eomes, that are associated with effector CTL [9, 11] and effector to 
memory CD8+ T cell transition [8, 12], respectively.  However, protein expression levels 
of T-bet and Eomes were not changed in the absence of STAT5 (Fig. 4.4C).  Another 
transcriptional access affecting CD8+ T cell terminal differentiation versus memory 
formation is the Blimp-1/Bcl-6 axis [14].  We saw a reduced level of Blimp-1 mRNA and 
an increased level of Bcl-6 mRNA in CD8+ T cells lacking STAT5 compared to wildtype 
(Table 4.1).  Interestingly, STAT5 has been shown to inhibit TFH differentiation in 
effector CD4+ T cells through increasing Blimp-1 expression and ultimately negatively 
regulating Bcl-6, which drives TFH fate [47, 48].  When we examined protein levels of Bcl-
6, we did not see differences (Fig 4.4C), but it remains possible that STAT5 impacts 
Blimp-1/Bcl-6 activity and thus may favor effector CTL differentiation in a manner 
similar to what is seen for CD4+ T cells. 
To test effector function more directly, we compared target cell lysis of STAT5 
WT and STAT5 CKO CD8+ T cells on day 8 postinfection.  We found approximately a 2-
fold decrease in killing on a per cell basis in the absence of STAT5 (Fig 4.4D).  This could 
be potentially explained by the lower levels of Perforin (Prf1) mRNA expressed by STAT5 
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CKO CTL compared to wild-type CTL (Table 4.1) and is consistent with a report that 
STAT5 binds the Prf1 promoter and drives Prf1 expression in CTL [4]. 
Over all, our data suggest that on a per cell basis, STAT5 deficiency has a 
modestly adverse impact on CTL effector function.  This is similar to the modest 
decrease in primary effector function seen in CTL that do not receive IL-2 signals [3], 
and it is possible that IL-2 driven effector function is mediated at least to some degree by 
STAT5.   However, taking into account that STAT5 does not affect peripheral localization 
of effector CTL and that STAT5 CKO CTL express GzB, cytokines, transcription factors, 
and FasL equal to wildtype (Fig. 4.4, Table 4.1), we conclude that STAT5 plays only a 
modest role in the development of primary effector CTL function.    
CTL differentiation is heterogeneous, including effector and memory precursor 
CD8+ T cell subsets that form part of the overall effector CTL pool. These two 
populations can be distinguished based on cell surface expression of KLRG1 and IL7Rα 
[9].  We and others have shown that IL-2 signals drive differentiation of terminal effector 
phenotype CTL during the primary response [2, 3].  To determine if IL-2 driven effector 
differentiation could be mediated by STAT5, we examined the differentiation of STAT5 
CKO antigen specific CD8+ T cells based on IL7Rα and KLRG1 expression following 
LCMV infection.  We found that total numbers of STAT5 CKO IL7Rαlo KLRG1hi 
phenotype CD8+ T cells were lower than STAT5 WT on day 8 postinfection, after 
contraction, and into memory (Fig. 4.5A).  However, whereas CD8+ T cells that do not 
receive IL-2 signals have reduced terminal effector phenotype CTLs, yet normal numbers 
of memory precursor and memory CD8+ T cells [3], we also found reduced numbers of 
IL7RαhiKLRG1lo phenotype CD8+ T cells in the absence of STAT5 (Fig. 4.5B).  
Additionally, while a proportion of IL7RαloKLRG1hi STAT5 WT still remain on day 40 






Figure 4.5 STAT5 signals during primary expansion are broadly important for all CD8+ 
T cells responding to acute infection. Graphs display the total number of KLRG1-hi, 
IL7Rα-lo (terminal effector phenotype) (A) and KLRG1-lo, IL7Rα-hi (memory 
precursor/memory phenotype) (B) at the indicated time points postinfection with 
LCMV-Arm for STAT5 WT and STAT5 CKO tetramer binding CD8+ T cells. C, 
Representative flow plots display the frequency of CD8+ T cell subsets as determined by 
KLRG1 and IL7Rα expression at the indicated time points for STAT5 WT and STAT5 
CKO tetramer binding CD8+ T cells.  Results are representative of 3-4 separate 
experiments. Error bars represent the SEM (n=3-4 per group). 
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point (Fig. 4.5C).  We conclude that in contrast to IL-2, STAT5 does not selectively drive 
differentiation of terminal effector phenotype CTL and is instead important the 
emergence of all effector CTL through the peak of expansion.  After clearance of 
pathogen, STAT5 signals are important for maintaining IL7Rαlo KLRG1hi phenotype CTL 
through contraction and into the memory phase. 
STAT5 signals are important for maintenance of tissue-residing 
memory CTL after pathogen clearance 
Memory CD8+ T cell populations were detectable in the spleen in the absence of 
STAT5 following LCMV infection, although at lower numbers than wildtype (Fig. 4.6A).  
Importantly, surviving memory cells did not express detectable STAT5 (Fig. 4.7A), 
indicating that memory CTL can emerge in the absence of STAT5, albeit at lower levels 
than wildtype.  We did not examine memory CD8+ T cell survival and homeostasis 
beyond 6 weeks postinfection due to the known role of IL-15 and IL-7, in long-term 
memory T cell maintenance [28].   At early memory time points, the absence of STAT5 
resulted in rapid loss of CD62Llo effector memory CTL in the spleen (Fig. 4.6B) and the 
preferential and specific decline of tissue-homing effector memory CTL in the liver (Fig. 
4.6C).  These findings are consistent with the role of IL-2 in effector memory CTL 
differentiation and suggest that IL-2-driven STAT5 activation is a key driver of effector 
memory CTL establishment [3, 5].  After pathogen clearance, STAT5 activity is 
particularly important for effector memory and tissue residing memory CD8+ T cell 
survival (Fig. 4.6B, C).  
 
STAT5 CKO memory CD8+ T cells have robust recall capacity 
Because IL-2 signals during primary CTL activation are required for the 
formation of memory CTL capable of robust secondary responses [3, 5], we assessed the  
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Figure 4.6 STAT5 signals are important for establishment and maintenance of effector 
memory and tissue residing CD8+ T cells.  A, Total numbers of antigen specific STAT5 
WT and STAT5 CKO CD8+ T cells in the spleen at the indicated time points post LCMV 
infection.  B, Histograms show representative CD62L staining in STAT5 WT and CKO 
CD8+ T cells in the spleen at indicated time points.  C, Ratio of H2Db-GP33-41 tetramer 
binding CD8+ T cells derived from WT counterpart compared to STAT5 counterpart 
YFP+CD8+ T cells in the indicated tissues at day 8 and day 40 postinfection.  Results are 
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Figure 4.7 Adoptive transfer strategy to determine recall capacity of STAT5 CKO memory 
CD8+ T cells.  A, Confirmation of deletion of STAT5 in memory CD8+ T cell populations.  
B, Schematic showing adoptive transfer strategy for determining recall capacity of 
STAT5 CKO CD8+ T cells compared to WT.  CD8+YFP+ memory T cells were FACS 
sorted from pooled spleens derived from either STAT5 WT or STAT5 CKO chimeras 
approximately 6 weeks postinfection with LCMV.  Sorted CD8+YFP+ T cells were 
analyzed for the composition of H2Db-GP33 and NP396 tetramer binding memory 
CD8+ T cells, then adoptively transferred into naïve B6 hosts.  The next day, the naïve 
B6 hosts were infected with LCMV clone 13.   
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ability of STAT5 WT and STAT5 CKO memory CTL to respond to rechallenge.  Prior to 
rechallenge, we verified that antigen specific memory CD8+YFP+ T cells from STAT5 
CKO chimeras did not express detectable STAT5 (Fig. 4.7A).  Direct rechallenge of 
memory phase bone marrow chimeras is difficult to interpret due to the inability to 
distinguish between recall responses by YFP+ memory CD8+ T cells and recruitment of 
YFP- memory or naïve CD8+ T cells that subsequently express YFP.  Therefore, we used 
an adoptive transfer strategy to determine recall capacity in the absence of STAT5.   
STAT5 WT or STAT5 CKO CD8+YFP+ memory CTL were FACS-purified from the spleens 
of mixed chimeras 6 weeks after LCMV infection, analyzed for frequency of tetramer+ 
cells and transferred into naïve B6 hosts.  Twenty-four hours after adoptive transfer, the 
naïve B6 hosts were infected with LCMV clone 13 to induce recall responses by YFP+ 
memory CD8+ T cells (Fig 4.7B).  Similar experiments were done using LCMV Armstrong 
or recombinant Listeria monocytogenes expressing GP33-41 (Lm-gp33) as a secondary 
stimulus. 
Antigen-specific STAT5 WT and STAT5 CKO YFP+CD8+ T cells were clearly 
visible in the spleens of the clone 13 infected hosts at day 5 postrechallenge (Fig. 4.8A).  
In contrast to the primary response, STAT5 CKO memory CD8+ T cells expanded at 
levels similar to wild-type when rechallenged (Fig. 4.8B-D). This is in striking contrast to 
the defective accumulation upon rechallenge of memory CD8+ T cells generated in the 
absence of IL-2 [3, 5].  As in the primary response, STAT5 CKO secondary CTLs express 
normal levels of GranzymeB (Fig. 4.9A), IFN-γ (Fig. 4.9B) and differentiation-associated 
transcription factors T-bet and Eomes (Fig. 4.9A).  When rechallenged with Lm-gp33, 
STAT5 CKO secondary CTLs trafficked to the liver normally (Fig. 4.9C).  There is a 
modest decrease in formation of secondary KLRG1hiIL7Rαlo phenotype CD8+ T cells in 





Figure 4.8 STAT5-deficient memory CD8+ T cells are capable of robust recall responses.  
A, Representative flow plots show the frequencies of antigen specific CD8+ STAT5 WT 
and STAT5 CKO secondary responders in the spleens of B6 hosts on day 5 postinfection 
with LCMV clone 13.  Bar graphs display the fold expansion of antigen specific STAT5 
WT and STAT5 CKO CD8+YFP+ cells on day 5 post rechallenge with (B) LCMV clone 13, 
(C) LCMV Armstrong, or (D) Lm-gp33 compared to numbers adoptively transferred 
prior to infection. Results are representative of 3-4 independent experiments and error 
bars represent the SEM (n=3-4 per group). 
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Figure 4.9 STAT5 is not required for secondary effector CTL differentiation.  A, 
Intracellular staining of STAT5 WT (black line) and STAT5 CKO (gray line) CD8+ T cells 
for GranzymeB, T-bet, and Eomes on day 5 post rechallenge  with LCMV clone 13 
(experiment performed as described in Fig 6A).  Gray shaded histograms are isotype 
controls.  B, Intracellular cytokine staining for IFN-γ was performed after ex vivo 
restimulation on day 5 postrechallenge.  Splenocytes were restimulated with GP33-41 or 
NP396-404 peptides in the presence of Golgi Plug.  C, Representative flow plots show the 
presence of secondary CTL in the liver of Lm-gp33 infected mice on day 5 postinfection.  
D, Bar graphs show the frequency of secondary KLRG1-hi, IL7Rα-lo phenotype CD8+ T 
cells within YFP+ populations on day 5 postrechallenge.  Results are representative of 3-


















































































































































indicate of in terms of secondary CD8+ T cell memory differentiation.  Thus, secondary 
effector CTL differentation does not require STAT5.  Overall, we conclude that IL-2-
driven programming of memory CD8+ T cells capable of robust secondary expansion is 
largely STAT5 independent. 
Discussion 
 
Our results demonstrate a broad role for STAT5 signaling in the primary 
response to infection in promoting the accumulation of effector CTL, and a more 
selective role for STAT5 in the survival of effector phenotype and establishment and 
survival of tissue residing memory CD8+ T cells after pathogen clearance.  A study using 
direct infection of Mx1-Cre Stat5fl/fl mice showed that BRDU incorporation of wildtype 
and STAT5-deficient CD8+ T cells on day 8 postinfection was the same [36], which 
suggests that differences in overall expansion seen in our experiments are likely due to 
poor survival of STAT5-deficient CD8+ T cells.  Additionally, the absence of IL-2 
signaling during the in vivo response to acute infection impacts survival while having 
little effect on cell division [5].  However, differences in early proliferation (prior to day 
5) could also contribute to lower expansion in the absence of STAT5. 
Consistent with reduced survival in the absence of STAT5, we did see reduced 
expression of the pro-survival molecule Bcl-XL in STAT5 CKO CD8+ T cells at day 8 
compared to WT, which was also seen for CD8+ T cells over that do not receive IL-2 
signals [3].  It is known that STAT proteins, including STAT5, can induce Bcl-xL in 
several cell types [49].  It is possible that IL-2 induced STAT5 could promote survival of 
CD8+ T cells during the primary response through induction of Bcl-xL.  However, T cells 
lacking Bcl-xL (all isoforms) were able to mount normal responses to Listeria 
monocytogenes infection [50].  Additionally, Bcl-xL can be regulated post-translationally.  
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Thus, the impact of differences in Bcl-XL mRNA levels during primary expansion in the 
absence of IL-2 and STAT5 signals are not clear. 
We find that STAT5 signals are broadly important for all effector CTL cell during 
primary expansion, suggesting that STAT5 does not drive CD8+ T cell fate decisions 
during the primary response.  This is in contrast to the specific role of IL-2 in 
preferentially promoting the differentiation of terminal effector phenotype CTL [3].  
Another γc family member, IL-21, also able to activate STAT5, though to a lesser degree 
than IL-2 [51], has recently been identified as being important in CD8+ T cell 
differentiation in the context of chronic [52-54] and acute infection [55].  Additional 
STAT5 activation during the primary response is likely stimulated by IL-7 and IL-15, and 
we have found that the combined absence of IL-2 and IL-15 enhances the defect in 
terminal effector CTL emergence during the primary response [3].  Our results suggest 
that STAT5 may have graded effects on CTL differentiation.  While the loss of potent 
STAT5 activation induced by IL-2 preferentially impacts terminal effector phenotype 
CTL formation, STAT5 activation induced by other cytokines may be sufficient for the 
differentiation of memory precursor CTL.  Complete loss of STAT5, however, results in a 
defect in both terminal effector phenotype and memory precursor CTL.  Therefore, while 
complete STAT5 deficiency does not reveal a binary role for STAT5 in promoting the 
differentiation of one subset or the other, our results suggest that the extent and/or 
duration of STAT5 activation impacts CD8+ T cell subset differentiation during the 
primary response, as well as providing broad survival signals during expansion. 
The cytokine IL-15 selectively promotes survival of terminal effector phenotype 
CTL after viral clearance [3, 56], while IL-7 promotes memory precursor phenotype 
CD8+ T cell survival during contraction [56].  Although both of these cytokines induce 
STAT5 signaling, we observed a switch from a broad requirement for STAT5 during 
expansion to a more selective requirement for its activity in the maintenance of effector 
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phenotype and long lived effector memory CD8+ T cells during contraction and into the 
memory phase.  This could be due to different levels of STAT5 activation induced by IL-
15 and IL-7 [57].  Alternatively, another report has shown that effector phenotype CD8+ 
T cells are more dependent on STAT5 signals for survival during contraction [35, 36].  
Collectively, these reports and ours emphasize that for different CD8+ T cells subsets, 
there appears to be differential usage of and access to common signaling cascades 
induced by common gamma chain cytokines. 
Importantly, we observed the emergence of a STAT5-deficient memory CD8+ T 
cell population 6 weeks after infection, albeit at lower levels than what was seen for 
wildtype.  This brings to question the survival signals that are used in the absence of 
STAT5 and to what degree these signals are used under normal conditions.  A recent 
report suggests that STAT5-independent survival signals could be utilized in the 
formation of memory CD8+ T cell populations [57], but the nature of those signals 
remain unknown.  A recent study showed that memory precursor CTLs were able to 
activate IL-15-induced PI3K/Akt more efficiently than effector phenotype CTLs [35].  
However, hyper-activation of this pathway was detrimental to long term survival of 
memory CD8+ T cells.  
Despite being a key mediator of IL-2 signals, we found that STAT5 was 
dispensable for the ability of memory CD8+ T cells to mount robust secondary responses 
and undergo secondary effector CTL differentiation.  This highlights a different 
requirement for STAT5 during primary and secondary CD8+ T cell responses, as STAT5-
deficient primary responses were reduced compared to wildtype.  Moreover, this is in 
striking contrast as to what is seen for memory CD8+ T cells generated in the absence of 
IL-2 signals, which fail to mount successful recall responses and fail to differentiate into 
secondary effector CTL [3, 5].  Thus, the mechanism by which IL-2 signals during the 
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primary response program memory CD8+ T cells is independent of STAT5 and remains 
to be defined.   
Alternative candidate pathways induced by IL-2 that could induce effective 
memory CTL differentiation include STAT3 and PI3K/Akt.  STAT3 signals are also 
induced by IL-2 [51], and a role for STAT3 in persistence of memory precursor CTL in 
mice [55] and CD8+ TCM formation in humans [58] has been suggested.  However, STAT3 
is efficiently activated by a variety of other cytokines [51, 59], and it seems unlikely that a 
major proportion of STAT3 activity during the primary CTL response is IL-2-dependent.  
Moreover, the phenotypes of STAT3 deficient and IL-2Rα deficient CD8+ T cells do not 
align, as IL-2 is important for terminal effector CTL [3] whereas STAT3 appears to be 
important for memory precursor phenotype CD8+ T cells [55].   
A more likely candidate is IL-2-dependent PI3K/Akt activation.  While this 
signaling pathway is induced in CD8+ T cells by a variety of sources, the additive effects 
of multiple signals, including IL-2, in the induction of PI3K/Akt activation for memory 
CD8+ T cell differentiation could be important.  Moreover, several recent reports have 
suggested that the kinase mTOR, which is downstram of PI3K/Akt activation, is a key 
regulator of effector and memory CTL fate decisions and survival [60-62].   Therefore, it 
seems likely that IL-2 mediates its effect of CTL differentiation at least in part through 
PI3K/Akt activation.   
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The work in this dissertation explores the role of IL-2, the related cytokine IL-15, 
and the transcription factor STAT5 in CD8+ T cell effector and memory fate decisions.  
As a result, we have a more detailed understanding of the role of cytokines and their 
signaling pathways in promoting effector CTL responses, the subsequent survival of 
CD8+ T cell subsets into the memory phase, and the programming of memory CD8+ T 
cells capable of protective recall responses. 
 In the case of IL-2, we find a role in both effector CTL differentiation as well as 
memory CD8+ T cell programming.  Two recent reports have also demonstrated a role 
for IL-2 in driving effector CTL differentiation.  These studies found that effector CTL 
differentiation was influenced by the concentration of IL-2 following activation[1] or by 
the length of time activated CTLs were able to incorporate high affinity IL-2 signals [2].  
Together with our report, these studies demonstrate a non-redundant role for IL-2 in 
enhancing effector CTL differentiation, survival and function.  Our report further 
demonstrates that in the complete absence of high affinity IL-2 signals, secondary 
effector CTL differentiation is dramatically impaired.   
Because our  studies found a role for IL-2 in promoting secondary CTL responses 
in both LCMV and Listeria infectious model systems [3, 4], we concluded that IL-2 
played a broad role in memory CTL differentiation in disparate model systems.  While 
the role of IL-2 in promoting secondary responses following LCMV infection have also 
been observed by another group [5], one recent study, while also reporting a role for IL-2 
in driving primary effector CTL differentiation following Listeria infection, found that 
the recall capacity of the resulting memory cells was IL-2 independent [6].  It remains 
possible therefore that the role of IL-2 may depend on the pathogenic stimulus.  Clearly 
the impact of IL-2 in driving the differentiation of effector and memory CTL requires 
further study.   
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One complicating factor may be the presence of redundancy within the immune 
system.  We examined the potential overlapping role of the cytokine IL-15 in CD8+ T cell 
differentiation, which is highly related to IL-2 in that its receptor shares both the β and γc 
subunits of the IL-2 receptor, which are involved in signal transduction.  We find that IL-
15 does not drive the differentiation of effector CTL and does not have a memory CD8+ T 
cell programming role as we have shown for IL-2.  Instead, IL-15 supports the survival of 
terminal effector CTL after pathogen clearance.  It is possible that the levels of IL-15 
available to T cells differ depending on the nature of the pathogenic stimulus, and our 
results do not rule out a potential role for IL-15 during primary T cell differentiation if 
present at high enough concentrations in other infectious model systems. IL-2, on the 
other hand, is secreted at high levels upon activation and is probably available to 
differentiating CTLs throughout the primary expansion phase. 
Several other cytokines, such as IL-7 and IL-21, also utilize the common gamma 
chain (γc) as a signaling component of their receptors, and these cytokines send a 
common TCR-independent proliferative signal via the STAT5 and STAT3 transcription 
factors [7].  It is not clear, however, whether the programming of functional memory 
cells by IL-2 represents a unique signal from IL-2 that IL-7, IL-21 or other γc family 
member cytokines are unable to deliver, or if it represents a common signal, that any 
member of the family could redundantly deliver during T cell activation and 
differentiation, were it present in sufficient amounts and its receptor expressed.  One 
intriguing candidate member of this family with similar induction kinetics is IL-21, 
which, like IL-2, is largely expressed by CD4+ T cells, is induced upon activation and 
promotes enhanced cytotoxicity by CD8+ T cells [8]. Furthermore, IL-21 has been shown 
to induce both Blimp-1 and Bcl-6 expression during B cell activation and differentiation, 
suggesting the intriguing possibility that IL-21 may play an effector/memory 
differentiation role for T cells [9]. Recent studies found that like IL-2 [5], IL-21 signals to 
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T cells were not required for primary CTL expansion but did promote their ability to 
control chronic infection [10-12].  Moreover, a recent study suggests that STAT3, which 
is induced by IL-21 and to a lesser degree by IL-2, may have a programming role in CD8+ 
T cell memory differentiation [13].   
How does IL-2 fit into current models of memory CD8+ T cell differentiation?  
The most likely model, as discussed in the Introduction, is a scenario in which activated 
CD8+ T cells commit to a fate of death after pathogen clearance or long-lived memory 
early during an immune response.  Within this fate decision, progressive differentiation 
will continue as environmental signals promote a more or less differentiated effector 
CD8+ state and ultimately affect the potential of a particular CD8+ T cell to populate the 
memory pool and to provide protection from reinfection. Considering that IL-2 plays a 
role in both effector CTL differentiation and memory CD8+ T cell programming [1-4], a 
goldilocks principle could be imagined.  An effector CTL may need to be pushed far 
enough into an effector differentiation program that it can “remember” or reaccess this 
program later in order to mount a successful recall response.  Exactly how this memory 
of an effector program could be obtained is not known, but epigenetic changes are likely 
a mechanism.  If too much or too strong of an IL-2 signal is received by a particular CTL, 
this may drive complete terminal differentiation resulting in death after pathogen 
clearance or more rapid disappearance from the memory pool.  Thus memory cells 
generated in the absence of IL-2 signals would be largely unable to enter an effector 
differentiation pathway upon reactivation.  Future studies are needed to identify 
epigenetic changes as well as changes in transcriptional activity that are influenced by 
IL-2 signals in differentiating CTL in vivo. 
 IL-2 potently activates the transcription factor STAT5, and in an attempt to 
understand the molecular nature of the IL-2 signal delivered to CD8+ T cells, we 
examined the role of STAT5 in CD8+ T cell effector and memory differentiation.  In 
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contrast to IL-2, which selectively drives the differentiation of terminal effector 
phenotype CTL, we found that STAT5 was broadly important for all CD8+ T cell subsets 
during the primary response.  In the context of our findings for both IL-2 and IL-15, our 
results could imply that STAT5 may have graded effects on CTL differentiation.  While 
the loss of potent STAT5 activation induced by IL-2 preferentially impacts effector 
phenotype CTL formation, STAT5 activation induced by other cytokines may be 
sufficient for the differentiation of memory precursor CTL.  Complete loss of STAT5, 
however, results in a defect in both effector phenotype and memory precursor CTL.  
Therefore, while complete STAT5 deficiency does not reveal a binary role for STAT5 in 
promoting the differentiation of one subset or the other, our results suggest that the 
extent and/or duration of STAT5 activation impacts CD8+ T cell subset differentiation 
during the primary response, as well as providing broad survival signals during 
expansion. 
Most strikingly, STAT5 was not required for robust recall responses and 
secondary effector CTL generation, which contrasts not only its own role during the 
primary response, but also differs from the role for IL-2 in memory CD8+ T cell 
programming [3, 4].  Thus, we conclude that IL-2 driven memory CD8+ T cell 
programming is independent of STAT5.  The molecular nature of the IL-2 signal still 
remains to be defined.  Alternative candidate pathways induced by IL-2 that could 
induce effective memory CD8+ T cell differentiation include STAT3 and PI3K/Akt.  
STAT3 signals are also induced by IL-2 [14], and a role for STAT3 in persistence of 
memory precursor CTL in mice [13] and CD8+ TCM formation in humans [15] has been 
suggested.  However, STAT3 is efficiently activated by a variety of other cytokines [7, 16], 
and it seems unlikely that a major proportion of STAT3 activity during the primary CTL 
response is IL-2-dependent.  A more likely candidate is IL-2-dependent PI3K/Akt 
activation.  While this signaling pathway is induced in CD8+ T cells by a variety of 
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sources, the additive effects of multiple signals, including IL-2, in the induction of 
PI3K/Akt activation for memory CD8+ T cell differentiation could be important.  
Moreover, several recent reports have suggested that the kinase mTOR, which is 
downstram of PI3K/Akt activation, is a key regulator of effector and memory CTL fate 
decisions and survival [17-19].  Therefore, it seems likely that IL-2 could mediate its 
effect of CTL differentiation and memory CD8+ T cell programming at least in part 
through PI3K/Akt activation.   
Our molecular understanding of CD8+ T cell effector and memory differentiation 
remains to be enhanced.  While signals to effector CTL during the primary response 
important for fate decisions have been identified, how these signals are incorporated and 
ultimately drive differentiation remains to be further explored.  Further studies 
examining signaling pathways, transcriptional networks, and epigenetic changes that 
drive CD8+ T cell fate decisions, as a result of IL-2 as well as other crucial signals, are 
essential in furthering our understanding of memory T cell biology and ultimately aid in 
design of vaccines and strategies aimed at immune modulation.  
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